Exploration of TRPV1 Splice Variant Expression in Rat Dorsal Root Ganglia Following Sciatic Nerve Injury by Andersen, Karl A.
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Summer 2010
Exploration of TRPV1 Splice Variant Expression in
Rat Dorsal Root Ganglia Following Sciatic Nerve
Injury
Karl A. Andersen
Follow this and additional works at: https://dsc.duq.edu/etd
This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Andersen, K. (2010). Exploration of TRPV1 Splice Variant Expression in Rat Dorsal Root Ganglia Following Sciatic Nerve Injury
(Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/263
  
EXPLORATION OF TRPV1 SPLICE VARIANT EXPRESSION IN RAT DORSAL 
ROOT GANGLIA FOLLOWING SCIATIC NERVE INJURY 
 
 
 
 
A Thesis 
Submitted to the Bayer School of Natural and 
Environmental Sciences 
 
 
Duquesne University 
 
In partial fulfillment of the requirements for  
the degree of Master of Science 
 
By 
Karl Andersen 
 
August 2010 
 
 iii
 
 
 
 
EXPLORATION OF TRPV1 SPLICE VARIANT EXPRESSION IN RAT DORSAL  
 
ROOT GANGLIA FOLLOWING SCIATIC NERVE INJURY 
 
 
 
 
 
 
 
By 
 
Karl Andersen 
 
Approved June 23, 2010 
 
 
 
______________________________  _______________________________ 
John A. Pollock, Ph.D. Brady Porter, Ph.D. 
Associate Professor of Biology Associate Professor of Biology 
(Thesis Director) (Committee Member) 
 
 
 
 
______________________________ ______________________________ 
David L. Somers, Ph.D., PT Michael Jensen-Seaman, Ph.D. 
Chair, Associate Professor, Assistant Professor of Biology 
Department of Physical Therapy (Committee Member) 
(Committee Member) 
 
 
 
______________________________ ______________________________ 
David W. Seybert, Ph.D. Philip E. Auron, Ph.D. 
Dean, Bayer School of Natural and  Chair, Professor, Department of  
Environmental Sciences Biological Sciences 
 
 iv
ABSTRACT 
 
EXPLORATION OF TRPV1 SPLICE VARIANT EXPRESSION IN RAT DORSAL 
ROOT GANGLIA FOLLOWING SCIATIC NERVE INJURY 
 
 
 
By 
Karl Andersen 
August 2010 
 
Thesis supervised by John A. Pollock, Ph.D.  
 Transient Receptor Potential Vanilloid 1 (TRPV1) is ligand-gated ion channel that 
plays an important role in the pain signaling pathway.  It is predominantly expressed by 
sensory neurons located in trigeminal ganglia or dorsal root ganglia (DRG).  TRPV1 has 
been shown to play a crucial role in the generation and maintenance of inflammatory and 
neuropathic pain.  The involvement of splice variants of TRPV1 in pain pathways is not 
well known.  In this study, the mRNA expression of TRPV1 and 3 splice variants 
(TRPV1.b, TRPV1.β, and TRPV1.var) in DRG was measured following chronic 
constriction injury of the sciatic nerve in rats.  This is the first study to isolate TRPV1.β 
in rat DRG.  The expression of TRPV1 mRNA was elevated following peripheral nerve 
damage, but not TRPV1.b, TRPV1.var or TRPV1.β.  These novel findings suggest that 
the expression of TRPV1 splice variants is not regulated by sciatic nerve injury. 
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Chapter 1 
 
INTRODUCTION 
 
Pain and its consequences 
 
 According to the International Association for the Study of Pain (IASP), pain is 
defined as, “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” [1] As implied by the 
definition, pain is a phenomenon that eludes easy classification.  It is shared among all 
humans and with most metazoan species in some form or another, but manifests in a 
myriad of ways.  One may experience pain in response to jamming a toe, touching a hot 
stove, or eating an ice cream sundae too quickly.  And at the same time, athletes and 
soldiers have reported feeling no pain following severe trauma, such as when a football 
player breaks a finger while running down field or when a soldier is wounded on the 
battlefield.  Understanding how our bodies generate and transmit painful signals is 
becoming one of the greatest challenges of modern medicine. 
 Researchers studying pain divide it into two broad categories: acute and chronic 
[2]. Acute pain is the type of pain that is associated with a diagnosable source, such as 
trauma, injury, or surgery. .  In most cases, acute pain has a defined period of time: 
usually the time it takes the body to heal itself.  And, acute pain can be relatively well 
controlled with medicines.  Chronic pain is a pain that persists, sometimes long after the 
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original injury has healed.  It can arise from a variety of sources, including cancer, 
arthritis, arachnoiditis (inflammation of the arachnoid membrane), and those are just a 
few of the diseases that have known etiologies.  Some diseases, such as fibromyalgia or 
complex regional pain syndrome, have no well-defined origins.  Sufferers of chronic pain 
often experience diminished quality of life and relationships, and are more likely to suffer 
from depression as a consequence [3]. 
 Extending beyond the suffering of the individual, pain has a serious effect on 
society.  Pain is a significant contributor to decreased work productivity, lost worker 
hours, and work performance.  In 2003, a study by Stewart et al. [4] found that common 
painful conditions, such as arthritis, migraines, back pain, and other musculoskeletal 
afflictions, resulted in the loss of $61.2 billion per year, and affected 13% of the total 
workforce during a two-week period. Additionally, this study did not include other types 
of pain such as dental pain, cancer pain, neuropathy, or pain associated with 
menstruation. Kathryn Weiner, director of the American Academy of Pain Management 
went so far as to say that pain is an epidemic in America [5].  She points out that in 1999, 
4 out 10 people responding to a survey were unable to obtain adequate pain management 
therapies for moderate to severe pain.  The cost of pain is expected to rise as a 
consequence of people working longer, and the estimated 75 million American baby 
boomers increasing in age.  
 Currently, the common pharmacological solutions to alleviating pain and, in 
particular, chronic pain, are not always effective.  Unlike other diseases, which can have 
targeted solutions, pain is treated in a nonspecific manner, usually relying on non-
steroidal anti-inflammatory drugs (NSAIDS), or opiods, such as morphine or codeine, to 
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control symptoms.  A consequence of these drugs freely circulating and interacting with 
various regions of our bodies is that they can have serious side effects [6].  The NSAIDs, 
such as acetominophen and ibuprofen, diminish mild to moderate pain by inhibiting 
cyclooxygenase (COX) enzymes, COX-1 and COX-2, throughout the body.  These two 
enzymes synthesize inflammatory molecules including prostaglandins, among others. 
Opiods create an analgesic effect by binding to opiod receptors within the central nervous 
system.  Though very effective at dulling the experience of moderate to severe pain, 
opiods have many side effects, ranging from mild to severe, including constipation, 
disorientation, and respiratory depression.  The continued usage of opiods can also lead 
to dependency and decreased efficiency, due to tolerance of the drugs. Opiods also have a 
greater potential for abuse and misuse [7,8,9]. 
Long-term, non-dependent, and effective pain management therapies are likely to 
increase in importance as more people suffer from chronic pain, especially since the 
current drugs are not adequately solving the problem [10, 11].  The key to cracking the 
problem of chronic pain will come from a greater understanding how painful stimuli are 
recognized, propagated, integrated, and interpreted as pain.  One of the goals of this 
project is to expand our understanding of the molecular basis for pain circuitry, which 
will allow us to disrupt it with fewer adverse consequences. 
How we feel pain 
 Like hunger, sleep, and thirst, pain is a powerful behavioral motivator.  It has the 
power to compel us to act, often in ways that are far different from our normal routine.  In 
a sense, it is the body’s alarm system.  It alerts us to possible damage to our bodies, and 
compels us to stop what we were doing, or to seek medical help if necessary.  Though we 
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now experience it in a multimodal, multifaceted way, pain first evolved as a simple 
protective mechanism, a way for the body to inform the brain that it has experienced 
harm of some sort, be it inflammation, injury, or trauma.   
 The actual sensation of pain originates at the peripheral terminals of primary 
afferent pain fibers, which are located in the skin and viscera.  They are responsible for 
monitoring the chemical, thermal and mechanical environment. These specialized nerves 
were given the name nociceptors by Charles Sherrington at the beginning of the 20th 
century [12,13].  They are unique among somatosensory neurons in that they respond to 
the same stimuli as all other neurons, but their threshold of activation is much higher 
[14].  Their sensory specification is also due to their possession of unique combinations 
of ion channels that are tuned to respond to only noxious stimuli.  Following activation at 
the nerve terminal, noxious signals are sent back to the cell body, which are largely 
located within dorsal root ganglia or trigeminal ganglia, and then to the central terminal, 
which is the interface between the central and peripheral nervous systems.  At the central 
terminal, the nociceptors form synapses with second order neurons in discrete regions of 
the dorsal horn, primarily within lamina I and II [15].  The signal is transferred from the 
ganglia to the central terminal in the form of neurotransmitters and neuropeptides, 
including, among others, substance P, Calcitonin gene-related peptide, and neuropeptide 
tyrosine [15].  From there, the noxious signals are relayed to discrete regions of the brain 
that are responsible for interpreting the signal as painful. 
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The Transient Receptor Potential Superfamily 
 Currently, there are 28 known mammalian members of the Transient Receptor 
Potential (TRP) protein channel superfamily.  They are divided into 6 sub-families.  The 
original TRP was defined by a physiological phenotype of a transient receptor potential 
in the electroretinograms of Drosophila melanogaster strains that had been chemically 
mutagenized [16].  Later work by Baruch Minke showed that the TRP protein played an 
intermediate role between photoreception and the opening of light-sensitive channels 
(Minke, 1982, Montell and Rubin).  In 1989 the trp locus was cloned from Drosophila 
and shown to have sequence similarity to Ca2+ channel genes [17]. 
Classification of the mammalian TRP proteins was decided on by the TRP Nomenclature 
committee in 2002 [18].  Members of the TRPC subfamily were named such because 
they are the ones that most closely resemble the first TRP gene isolated from Drosophila 
[19].  These members are termed “canonical” TRPs based on sequence homology.  The 
other five subfamilies are named after the first protein of that subfamily that was defined.  
The TRPV1 subfamily was named after the vanilloid receptor 1.  The TRPM subfamily 
was named after melastatin, which is a predicted tumor suppressor gene [20].  TRPML 
was named after the protein mucolipin, which, when mutated, causes the disease 
Mucolipidosis type IV [21, 22].  The TRPA subfamily was named after its founder gene 
ankyrin-like with transmembrane domains 1 (ANKTM1) [23].  TRPP was named after 
polycystin-1, which when mutated, causes the disease autosomal dominant polycystic 
kidney disease (ADPKD) [19, 24]. 
 Structurally, all TRP channels are similar, sharing six transmembrane domains, a 
pore-loop between the fifth and sixth domains, and cytoplasmic NH2 and COOH termini 
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[25].  Almost all are calcium-permeable cation channels [26].  TRP channels respond to a 
wide array of stimuli, including heat, cold, osmotic stress, pH changes, and a wide variety 
of chemicals, including menthol, allicin, mustard oils, and even jellyfish toxins 
[27,28,29,30].  TRP channels also act as taste receptors and contribute to the detection of 
bitter, sweet, and umami [31].  TRPs relay information back to the soma by altering Ca++ 
concentrations, either by directly permitting its entrance into the cell, or by allowing 
other cations into the cell that then activate pathways to release Ca++ from internal stores.  
This flux of Ca++ ions causes the cell to become depolarized and result in an action 
potential, informing the brain of the painful stimuli [19].  Like other channels, members 
of the TRP family are known to form heterotetramers or homotetramers, depending on 
the specific protein, which allows the complex to be more sensitive to specific stimuli 
and be more selective of which cation passes through [32].  Normally, the channels are 
homotetramers, but a few cases of heteromerization between proteins, such as between 
TRPV1 and TRPA1, and TRPV1 and TRPV2, have been reported [10, 33].   
 Within this diverse superfamily, a subset of the proteins are involved in the 
transduction of painful or noxious stimuli.  These pain-sensing TRPs are TRPM8, 
TRPA1, and TRPV1-TRPV4.  These proteins are often referred to as ThermoTRPs since 
they are partially responsible for sensing different temperatures.  The vanilloid TRPs 
sense warm to painfully hot temperatures, and TRPM8 and TRPA1 are involved in 
sensing cool and cold temperatures [30, 34].   
Transient Receptor Potential Vanilloid 1 (TRPV1) 
 Of the known pain transducing TRPs, the best understood one is Transient 
Receptor Potential Vanilloid 1 (TRPV1), a member of the vanilloid subfamily of the TRP 
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superfamily.  First cloned and described by Caterina et al. in 1997 [35], TRPV1 is 
perhaps best known as the capsaicin receptor.  Capsaicin is a small, vanilloid molecule 
responsible for the spicy flavor of chili peppers. TRPV1, however, responds to more than 
just capsaicin, as it is a polymodal nociceptor, and can integrate multiple additional 
stimuli including noxious heat detection (≥43°C), protons, low pH, certain jellyfish and 
spider toxins, camphor, and allicin  (a pungent molecule found in onions and garlic) [28, 
36, 37].  The channel is also sensitized by a whole host of intracellular molecules, 
including bradykinin, nerve growth factor, prostaglandins, ATP, calmodulin, 
anandamine, diacylglycerol, and eicosanoids [38, 39, 40, 41].  Most of these molecules 
sensitize TRPV1 by directly or indirectly phosphorylating the protein [42].  Sensitization 
of TRPV1 can lower the thermal threshold to normal body temperatures [43], 
contributing to thermal hyperalgesia, a symptom of chronic pain states. 
 TRPV1 is primarily expressed in capsaicin-sensitive bipolar neurons whose 
somata are most often located in dorsal root ganglia (DRG) or trigeminal ganglia [42, 
44].  This subpopulation of primary afferent neurons are usually lightly myelinated (Aδ 
fibers) or unmyelinated (C fibers) [41, 45].  TRPV1 expression is not limited to neurons 
innervating the skin or musculoskeletal system, and has been identified in neurons 
innervating the urinary tract [46,47], the cardiovascular system [48,49], and the mucous 
membranes of the mouth and esophagus [35].  The presence of TRPV1 has also been 
confirmed in the CNS, including the hypothalamus and substantia nigra [50,51].  The 
expression of TRPV1 in non-neuronal tissue is far lower than in neuronal tissue [52].  
Like other TRP channels, TRPV1 is an ion channel, and is relatively selective for Ca++ 
and Mg++ [43].  
Karl A. Andersen 
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 The role of TRPV1 as a nociceptor has been widely documented in a variety of 
different acute, chronic, and neuropathic pain models and diseases.  Earlier studies have 
shown that capsaicin alone can cause hyperalgesia (the reduction of pain thresholds) and 
pain-like symptoms in animals and humans [53,54].  TRPV1 has also been shown to be 
associated with painful diseases such as diabetic neuropathy, chronic pancreatitis, cancer 
pain, osteoarthiritis, and gastrointestinal diseases [55,56,57,58,59].  The role of TRPV1 
as a nociceptor has also been demonstrated with TRPV1 knockout mice [60,61].  These 
trpv1-/- mice display normal responses to noxious heat, but do not experience the same 
amount of hyperalgesia that usually accompanies inflammatory pain [60]. 
 In the past 10 years, many studies have been conducted to determine if TRPV1 
expression is altered by disease or injury.  In a study of rats having received partial sciatic 
nerve ligation, or lumbar level 5 spinal nerve ligation, TRPV1 protein expression was 
elevated in uninjured DRG somata [62].  In the spine, TRPV1 levels have also been 
shown to be elevated in expression following sciatic nerve injury [63].  In cervical DRG, 
TRPV1 expression was also increased, following the administration of complete Freund’s 
adjuvant to the forepaws of rats [64].  While numerous sources demonstrate that TRPV1 
protein levels increase via immunohistochemistry or western blotting, fewer sources 
show that disease or pain models induce an increase in TRPV1 mRNA expression in 
DRG tissue.  A study using a peripheral nerve injury model found that mRNA for 
TRPA1, TRPM8, and TRPV2 increased in DRG tissue, but not TRPV1.  Another study 
that measured TRPV1 mRNA levels in DRG tissue using an oligonucleotide probe 
(complementary to bases 2581–2625 of rat V1 sequence) found that TRPV1 levels 
increased in lumbar level 4 (L4) and decreased in L5 following a different nerve injury 
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model [65].  A possible explanation for the discrepancy between the expression 
differences of TRPV1 protein and mRNA is that not all mRNA studies conducted tissue 
specific analyses.  The contribution of nerves to the sciatic nerve is not equal between 
DRG levels, so one would not expect to see equal changes in TRPV1 mRNA expression 
in the soma of these different tissue samples.  Furthermore, the combination of RNA 
from different DRGs would diminish apparent TRP mRNA expression since any increase 
found in one specific tissue would be diluted by the addition of RNA from the other 
tissues.  Bree Zeyzus, a former graduate student of the Pollock Lab, sought to shed light 
on this problem by performing a study where she analyzed TRPV1 mRNA expression in 
a tissue specific manner following induction of chronic pain [66]. 
Splice variants of TRPV1 
 The second focus of this research project was to determine the contribution of 
alternatively spliced variants of the TRPV1 gene to nocioceptive pathways.  Put simply, 
splice variants are different mRNAs produced from the same gene. The mRNAs will 
produce protein isoforms that have a different amino acid composition from the canonical 
form, and consequently may have different roles or functions within the cell.  This 
violation of the dogma “one gene, one protein” allows organisms to economically 
generate a larger proteome without having to maintain extra genes.  These additional 
peptides can have different ligand binding properties, allosteric properties, or enzymyatic 
activity [67].  Reliance on alternative splicing to generate novel polypeptides instead of 
genes, however, makes organisms more susceptible to problems if the alternative splicing 
mechanism is disrupted.  In the brain, for example, the Tau splice isoforms are involved 
in microtubule formation and stabilization.  Errors in the alternative splicing of Tau 
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contribute to neuropathologies such as Alzheimer’s disease [68].  One example of 
expression being regulated by alternative splicing is that variant mRNA transcripts can be 
created in order to generate a premature termination codon that targets the transcript to be 
destroyed via the nonsense-mediated decay pathway rather than turned into proteins [69].  
This process can serve as an additional check-point to halt the expression of functional 
proteins.  In the case of TRPV1, splice variants may serve to modulate the sensitivity and 
activity of the mature channel [70]; act as dominant negative regulators [71], altering the 
expression of mature channels; and serve non-nociceptive purposes, such as detecting 
salts in taste receptor cells [72].  
 The process that produces splice variants is called alternative splicing of pre-
mRNA.  Inside the nucleus, alternative splicing begins with the transcription of DNA into 
RNA.  The large enzyme complex, RNA polymerase II, faithfully copies the entire 
TRPV1 gene sequence, including both exons and introns.  Exons are smaller DNA 
segments within the gene sequence that contain the instructions for amino acid synthesis.  
The introns are generally larger segments of DNA that intervene between the exons and 
contain regulatory elements or unknown elements.  After transcription has occurred, the 
pre-mRNA molecule typically undergoes a series of modifications that include the 
addition of the 7-methylguanosine cap to the 5’ end of the primary transcript, 
polyadenylation of the 3’ end, and the removal of introns, which are not needed for 
translation.  The removal of introns is a complicated process called mRNA splicing, and 
is carried out by a ribonucleoprotein complex called the spliceosome.  The spliceosome is 
one of the largest complexes in the cell, consisting of over 200 proteins and at least 5 
small nuclear RNA molecules [73].  The spliceosome’s ability to distinguish exons from 
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introns is not completely understood, but the two major contributing components are 
splice site consensus sequences and flanking regulatory regions called intronic or exonic 
splicing enhancers or silencers [74].  Splice site consensus sequences are conserved 
recognition sites for the spliceosome situated at exon/intron borders [67,75].  There are 
unique consensus sequences at the start and finish of intronic sequences; the beginning of 
an intron almost always begins with the nucleotides GU and ends with the nucleotides 
AG.  Exonic and intronic splice site enchancers or silencers help mediate the splicing 
process by serving as binding sites for proteins that guide or repel the spliceosome 
subunits from assembling at nearby splice sites [74].   
 One reason that alternative splicing is such an important and powerful process is 
that it is not uniform in its occurrence.  The same gene can undergo alternative splicing in 
a tissue-dependent or developmental-dependent manner allowing for very precise 
regulation to be maintained throughout the body, and over time.  One famous example of 
alternative splicing occurs during the sex-determination process in Drosophila 
melanogaster.  The protein Sex lethal is only expressed in female cells, and it suppresses 
certain splicing patterns of pre-mRNA transcripts that would lead to male development 
[67].  The pattern of alternative splicing is also not uniform as one gene can have many 
different splicing combinations, allowing for hundreds or thousands of different isoforms.  
Currently, the Drosophila gene Down syndrome cell-adhesion molecule (Dscam) is the 
leader, with a possible 38,016 different isoforms [75].   
 Since its initial discovery, many different forms of alternative splicing have been 
identified (Figure 1).  The different types of alternative splicing include retained introns, 
alternative 3’ or 5’ splice sites, alternative translational start sites, cassette exons (entire 
Karl A. Andersen 
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exons that are removed), and mutually exclusive exons, among other types.  See for 
examples of alternative splicing.  Alternative splicing was once thought to be a relatively 
rare phenomenon, but recent analyses have suggested that anywhere from 60-90% of all 
human genes undergo alternative splicing [76].  This finding reconciles the difference 
between the >100,000 observed unique polypeptides and the 20,000-25,000 known genes 
in humans. 
Karl A. Andersen 
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Figure 1.  Different examples of alternative splicing. 
(a) Retained intron, (b) competing 5’-splice sites (c) cassette exons, (d) mutually 
exclusive exons.  Splicing patterns are illustrated by the diagonal black lines.  Exons are 
denoted by the rectangles.  Blue exons are constitutive; alternatively spliced segments are 
shown by the striped magenta boxes.   
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 For TRPV1, there are currently 7 reported splice variants between humans, mice, 
and rats in the published literature for TRPV1 (Table 1).  These variants are named 
TRPV1.b [70], TRPV1.β [71], TRPV1.var [78], TRPV1.5’sv [79], stretch-inactivated 
channel (SIC) [80], and two unnamed variants I have referred to as TRPV1.son [81] and 
TRPV1.ais [72].  TRPV1.son was identified in the supraoptic nucleus of mice.  The SIC 
variant is controversial since it is allegedly a product of trans alternative splicing between 
TRPV1 (exons 6-14) and the C-terminal domain of TRPV4.  It has not been 
independently confirmed [81,82].  Interestingly, 5 of the variants are generated from 
splicing events occurring in what will be the cytosolic N-terminal region of the mature 
protein, and all of them have splicing events occurring in the seventh exon, except 
TRPV1.var. TRPV1.β is both examples of alternate 3’ splicing, utilizing cryptic splice 
sites to truncate exon 7 by 60 and 30 nucleotides, respectively.  TRPV1.b is an example 
of a cassette exon, where the entire seventh exon is splice out.  And TRPV1.var is an 
example of both an alternative transcriptional start site and a retained 110 base pair intron 
between exons 5 and 6.  Though similar in splicing activity, these splice variants were 
isolated in three different organisms: human, rat, and mouse.  The exact role and function 
of each of these splice variants is not settled, but the majority exert their effect by altering 
the channel’s sensitivity [70] or act as dominant negative regulators [71,78].  
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Table 1. Known splice variants of TRPV1 and those discussed in this study 
Name Splicing 
Event 
Original 
Species 
Tissue Origin Genbank 
Entry Reference 
TRPV1.var Retained intron 
between exons 
5 and 6 
Rat Kidney N/A Tian et al. 
(2006) [78] 
TRPV1.SIC Trans splicing 
of TRPV1 and 
TRPV4 
Rat Trigeminal and 
Dorsal Root 
Ganglia, 
Kidney 
AB015231.3 Schumacher et 
al. (2000) [80] 
TRPV1.5’sv Translation 
begins at exon 
5 and exon 7 is 
spliced out 
Rat Dorsal Root 
Ganglia 
AF158248.2 Schumacher et 
al. (2000) [79] 
TRPV1.b Exon 7 is 
spliced out 
Human Human Brain AY986821.1 Lu et al. (2005) 
[70] 
TRPV1.β Exon 7 is 
truncated by 30 
bp 
Mouse Dorsal Root 
Ganglia 
AY452084.1 Wang et al. 
(2004) [71] 
TRPV1.ais Unspecified Rat 
Mouse 
Tongue N/A Lyall et al. 
(2005) [72] 
TRPV1.SON Splicing in N-
terminal region 
Mouse Brain N/A Sharif et al. 
(2006) [81] 
 
 While the role of these variants has been postulated under normal conditions, 
virtually no information is available about how these isoforms behave under different 
conditions, including neuropathic pain states.  So far, only two paper have been published 
that attempt to describe how the expression of TRPV1.b is affected by different 
environmental factors [83,84].  Vos et al. (2006) showed that TRPV1.b results of the first 
paper showed that overexpression of TRPV1.b in HEK cells attenuates TRPV1’s 
response to capsaicin, heat, and protons.  Subsequently, Charrua et al. (2008) showed that 
TRPV1.b expression is downregulated in the DRGs of rats injected with 
cyclophosphamide, a compound that induces bladder inflammation and models the 
human disease cystitis. 
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Neuropeptide Y and Growth-associated Protein 43 
 In this study, the changes in expression of Neuropeptide Y (NPY) and Growth-
associated Protein 43 (Gap43), in addition to the traditional behavioral tests normally 
conducted, serve as positive molecular controls for the Chronic Constriction Injury (CCI) 
model of neuropathic pain.  NPY, like TRPV1, is another gene that is involved in the 
pain transduction pathway [85].  Unlike TRPV1, which forms ion channels located in 
nerve terminals and is a nocioceptor, NPY is a peptide neurotransmitter released by 
primary afferent neurons located in the Dorsal Root Ganglia and received by neurons 
located in the substantia gelatinosa region of the spinal cord [85].  In animal models of 
neuropathic pain, NPY has been shown to be massively upregulated [86,87].  It is 
believed that this increase in expression results in the decrease of action potentials in 
post-synaptic neurons by decreasing the influx of calcium ions, thereby decreasing the 
activation of Ca++ sensitive K+ channels [85,88]. The lowered activation of Ca++ 
sensitive K+ channels diminishes the intensity of the pain perceived by organism.  The 
increase in NPY, therefore, is indicative that trauma to the nerve has occurred. 
 Gap43 is a growth-associated protein highly expressed in the growth cones of 
elongating axons. Its expression decreases after the target has been innervated [89].  In 
addition to its developmental role, Gap43 expression is differently expressed following 
neuronal tissue damage or inflammation, which has been demonstrated in many different 
animal neuropathy models [89,90,91].  Unlike NPY or TRPV1, Gap43 cannot be used to 
verify that a specific type of neuropathic pain state has been induced because it is not 
involved in the transduction of painful stimuli.  However, it can be used to verify that 
trauma has been caused to peripheral nervous tissue.   
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Specific aims  
This study began with two hypotheses.  The first is that TRPV1 mRNA levels are altered 
in the dorsal root ganglia of Sprague Dawley rats following a peripheral nerve injury in a 
tissue-specific manner; the second is that mRNA levels of alternatively spliced isoforms 
of TRPV1 are also altered following a peripheral nerve injury.  A third hypothesis was 
added midway through the study: that TRPV1 protein expression is increased in the 
dorsal root ganglia following a peripheral nerve injury. 
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Figure 2.  Dorsal view of Rat Neuroanatomy 
 From bottom to top are the L6, L5, L4, and L3 dorsal root ganglia projecting from the 
spinal cord.  Attached to each of these dorsal root ganglia are the axons that give rise to 
spinal nerves.  The spinal nerves combine to form the sciatic nerve mid-thigh.  The axons 
from L4 and L5 constitute 98-99% of the total number of axons that comprise the sciatic 
nerve.  L3 is suggested to contribute ~1.2% of total axons.  The contribution to the sciatic 
nerve from L6 is variable and at most contributes 0.4% of the total axons.  The autoclips 
shown mid-thigh are used to close the skin post-surgery (see methods). 
 
Artwork kindly provided by Mr. Robert Hoggard. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
Chronic constriction injury 
 This study was approved by the Institutional Animal Care and Usage Committee 
of Duquesne University.  Twenty-two adult male Sprague-Dawley rats (Hilltop Lab 
Animals, Inc., Scottdale, PA, 212g) were used for the experiment.   
 The Chronic Constriction Injury (CCI) procedure, which was developed by 
Bennet and Xie [92] is used to simulate in rats the human neuropathic condition called 
Chronic Regional Pain Syndrome II (CPSII).  CPSII is a disease that can occur after 
damage to a peripheral nerve, such as the sciatic nerve, has occurred.  Symptoms of 
CPSII include spontaneous pain, hypersensitivity of the skin, mottling of the skin, and 
distal extremity swelling [93,94].  All training necessary for compliance with IACUC and 
the project was received from Dr. Somers, a professor of the Physical Therapy 
department at Duquesne University.  He is an expert at performing this surgery and has 
used it extensively in his own research [94,95,96].  Rats undergoing CCI were 
anesthetized with sodium pentobarbital (50 mg/kg) via intraperitoneal injections.  To 
confirm that the rats were sufficiently anesthetized, the tail-pinch and leg withdrawal 
tests were performed.  Prior to surgery, the entire right leg and a portion of the lower 
back is shaved with an electric razor.  The surgical site, the rear right thigh, was depilated 
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with Nair, a commercial hair-removal product.  Betadine, a povidone-iodine solution, 
was applied to leg to help prevent infections from occurring.  The surgeries began with an 
incision in the mid-thigh region.  The sciatic nerve was exposed by separating the 
Gluteus superficialis and biceps femoris muscles.  To liberate the sciatic nerve, the fascia 
that keeps it attached to the biceps femoris was cut.  Once free, four 4.0 chromic gut 
sutures were loosely tied around the sciatic nerve in 1mm intervals.  Care was taken to 
prevent the sutures from being overly tight, such that blood flow through the epineurial 
vasculature was not stopped.  During the procedure, animals were administered 
additional small doses of anesthetic (~6mg/kg) to maintain the correct amount of 
anesthesia during the procedure.  The wound was closed in layers, using 4.0 silk sutures 
to sew the muscles back together and autoclips to close the skin.  See Figure 3 for details 
and photographs of the procedure. Two other groups of animals were used in this study: 
control and sham animals.  Sham animals underwent the surgery as described above, but 
sutures were not tied around the sciatic nerve.  The control animals were not operated on, 
nor did they receive any anesthetic. 
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Figure 3.  Chronic Constriction Injury Surgery 
 
(A)Pre-surgery.  The rat is anesthetized with pentobarbital.  Then its rear leg is shaved, depiliated, 
and treated with betadine to sterilize the surgical site. 
(B) Surgery.  An incision is made to separate the gluteus superficialis from the biceps femoris, 
exposing the sciatic nerve.  The forceps are shown pulling the biceps femoris away from the 
gluteus superficialis, exposing the sciatic nerve.   
(C) Post-surgery.  The muscles are sewn back together and the skin is closed with autoclips.  The 
still anesthetized rat is then returned to its cage.  
(D) Ligated sciatic nerve.  Four 4.0 sutures are tied around the sciatic nerve.  The lack of 
perfusion is a result of the photograph being taken post-mortem. 
(E) Sketch of the sciatic nerve with sutures in place.  The spinal cord and the combined L4 and 
L5 spinal nerves are shown.  These two spinal nerves form the bulk of the sciatic nerve.   
 
Photograph (D) kindly provided by Bree Zeyzus Johns 
Artwork (E) kindly provided by Mr. Robert Hoggard. 
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Behavioral assessment 
 Two behavioral tests were performed on day 0, the day on which the CCI and 
sham animals underwent surgery, and again on days 8 and 11 post-operation.  Baseline 
behavioral assessments were performed prior to any operation.  These tests were used to 
determine if mechanical allodynia (pain felt from stimuli that normally do not cause pain) 
or thermal hyperalgesia (an increased pain sensation) had been induced; both symptoms 
are common characteristics of neuropathic pain caused by the CCI procedure.  A timeline 
for the assessment procedure can be seen below: 
 
Figure 4. Experimental Timeline for Animal Work 
 
Mechanical and thermal baseline pain assessments were conducted for the three 
treatment groups at day 0 prior to any surgical procedures.  Pain assessments were 
repeated at days 9 and 11 post-operation.  11 animals (3 control, 4 sham-treatment, and 
4 CCI-treatment) were sacrificed on days 9 and 11.  DRGs were dissected out and 
stored for further use. 
 
On each day of testing, mechanical allodynia tests were performed first.  Testing for 
mechanical allodynia was performed by using calibrated Semmes-Weinsten 
monofilaments.  To ensure that any response would be correlated with the ligation of the 
sciatic nerve, the monofilaments were only applied to plantar surface of the rats’ right 
rear paw, which is an area only innervated by that nerve.  The rats were placed in 
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plexiglass boxes with exposed wire bottoms.  They were then allowed to habituate to this 
environment for 5 minutes.  Then, the filaments were applied to one paw at a time in 
order of thickness, from thinnest to thickest (0.41, 1.2, 3.63, 8.51, 15.13g).  The number 
of withdrawals per paw was recorded for each filament.  To prevent stimulation fatigue, 
each paw only received 5 pokes from one filament in one trial, and a total of two trials 
were performed per filament.  One trial consisted of each paw being poked 5 times.  Each 
trial was separated by five minutes.  The testing was complete when an animal was poked 
with all filaments or when a rat withdrew from all 10 pushes for a single filament. 
 To determine the 50% withdrawal threshold for each rat, a linear regression 
method was used.  The 50% withdrawal threshold is the calculated force (g) at which a 
rat will withdraw its paw 5 out of 10 pokes from one filament.  If the calculated value 
exceeds 15.13g, the force to deflect the thickest filament, then that value was recorded as 
the 50% withdrawal value.  The formula for determining the 50% withdrawal value can 
be calculated using the formula below: 
Normalized 50% withdrawal threshold (WT) = Post-Surgery (50% WT right paw 
– 50% WT left paw) – Baseline (50% WT right paw – 50% WT left paw). 
 
For each treatment group, all normalized withdrawal latencies were averaged, and the 
mean values were compared using the Kruskal-Wallis 1-Way ANOVA by Ranks Test.  
This was done for day 8 and day 11. 
 Following the mechanical sensitivity tests, I allowed the rats to rest in their home 
cages for 5 minutes before performing the thermal sensitivity test, which measured 
thermal hyperalgesia.  Each rat was placed inside of a plexiglass chamber on top of the 
radiant heat source and allowed to habituate to the chamber for 5 minutes.  After the 
habituation period was completed, the glass beneath the plantar portion of each rear paw 
was heated, though only one paw was irradiated at a time.  The rats were allowed 5 
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minutes of rest between irradiation treatments.  The source of heat for this apparatus 
came from a slide projector bulb that is focused through a fixed diameter aperture.  The 
irradiation began when an operator-controlled switch was thrown, and stopped either 
when the rat raised its paw, which interrupted a photocell that receives reflected light off 
of the paw, or when the irradiation had occurred for the maximum period of 20 seconds.  
Each paw received five treatments, which were averaged to produce a mean withdrawal 
latency. Withdrawal latencies were measured in hundredths of a second.  The formula 
used to calculate each rat’s normalized withdrawal latency is as follows: 
 Normalized Withdrawal (WD) Latency = Post-Surgery (WD latency right paw –  
         WD latency left paw) – Baseline (WD latency right paw – WD latency left paw). 
 
For each treatment group, all normalized withdrawal latencies were averaged, and the 
mean values were compared using the Kruskal-Wallis 1-Way ANOVA by Ranks Test.  
This was done for day 8 and day 11.  The normalization process accounts for changes in 
behavior over a period of time, and any differences in response between a rat’s 
contralateral and ipsilateral paws.  See Figure 5 for details. 
 Nocifensor signs of behavior were observed during the course of testing, but no 
systematic record of their occurrence was kept.  The types of behavior that were observed 
included paw-licking, paw-waving, paw-guarding, and defensive posturing.  Paw-licking 
and paw waving would occur rapidly after a paw had been poked or irradiated.  Paw-
guarding is defined as the prolonged raising of the affected paw off the ground.  Its 
occurrence was noted more often during the middle of a testing period and between 
rounds of testing.  Defensive posturing would occur when a rat would not stand with all 
four paws on the ground, and instead would either lie on its side or stand on its two rear 
feet, preventing me from testing it. 
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Figure 5. Behavioral Testing Setup 
(A) Thermal pain assessment.  Rats were placed inside plexiglass boxes on top of the 
testing apparatus.  Thermal hyperalgesia was tested by focusing a radiant heat source 
onto the glass beneath their rear paws.  Withdrawal was recorded in milliseconds. 
(B) Plantar portion of the rear paws.  The arrowheads are pointed at the plantar portion of 
the rear paws, which is between the the heel and the pads at the front of the paws. 
(C) Mechanical pain assessment.  Rats were placed inside of plexiglass boxes atop of a 
wire grid.  Mechanical allodynia was tested by poking the plantar portion of the rats’ hind 
paws with calibrated monofilaments. 
 
Dorsal root ganglia removal 
 At days 9 and 12 post-operation, the ipsilateral and contralateral dorsal root 
ganglia (DRG) from lumbar levels 2-6 were removed. On each day, 3 control, 4 CCI, and 
4 Sham animals were sacrificed (n = 11 per collection day).  First, the animals were 
anesthetized with sodium pentobarbital (50mg/kg) intraperitonealy.  The tail-pinch and 
leg withdrawal tests were again employed to ensure deep anesthetization.  Then an 
incision was made along the length of the spine, exposing the muscles and spine.  The 
muscles attached to spine were removed, exposing the spinous and lateral processes of 
the lumbar vertebrae.  With medical rongeurs, the spinous processes were removed.  The 
dorsal lumbar vertebrae were then shaved down using a Dremel drill.  The remaining 
bone was removed with Rongeurs and forceps, exposing the spinal cord and DRGs. The 
DRGs were removed with forceps and microscissors.  Once extracted, the DRGs were 
immediately submerged in RNAlater (Qiagen), a solution designed to stabilize RNA, and 
placed on ice until they could be transferred to the -80C freezer.  After all of the DRGs 
were removed, the rats were sacrificed via thoracotomy.  See Figure 2 for an illustration 
of rat neural anatomy and Figure 6 for photographs of the procedure.  
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Figure 6. Dorsal Root Ganglia Removal 
(A) The skin and muscle are removed to expose vertebrae.  Spinal processes are removed 
and the bone is shaved down. 
(B) Bone is removed with forceps and rongeurs to expose the spinal cord. 
(C) The remaining bone has been removed, revealing underlying spinal column and 
dorsal root ganglia (L2-L6 exposed).  Arrow points to left L5 DRG.  
(D) Lateral view of exposed spinal column and dorsal root ganglia (L2-L6 exposed). The 
Arrow points to left L5 DRG. 
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RNA isolation and cDNA generation. 
 Tissue samples were removed from the RNAlater solution, cut into small 
fragments, placed into a lysis buffer, and then run over QiaShredder columns to ensure 
complete homogenization.  Total RNA was then extracted using the RNeasy kit (Qiagen).  
To prevent any genomic DNA contamination, each RNA sample was treated with DNase 
I (Invitrogen). Complementary DNA (cDNA) was generated using poly-dT primers 
during the reverse-transcription reaction (Superscript III, Invitrogen).  Poly-dT primers 
only target mRNA transcripts by annealing to their polyA tails.  2µL of RNA was used in 
each reaction.  For each tissue sample, two 100µL pools of cDNA were generated by 
combining five 20µL reactions.  The 5 reactions were combined because Zeyzus [66] 
found that each reaction would produce a variable concentration of cDNA, and 
combining them would produce a uniform cDNA concentration.  cDNA samples were 
stored at -20C until used.  Each 100µL pool of cDNA was tested separately. 
cDNA analysis and RNA quantification 
 RNA was quantified using two similar techniques, often referred to as 1-step and 
2-step quantitative PCR (qPCR).  2-step qPCR was performed using cDNA prepared in 
the manner described previously, and 1-step qPCR was performed using RNA as the 
template.  The difference between 1-step qPCR and 2-step qPCR is that for 1-step 
reactions the reverse-transcription and amplification occur in the same test tube, and gene 
specific primers are used instead of poly-dT primers during the reverse-transcription.  
Karl A. Andersen 
 29 
Samples were analyzed in triplicate, and at least twice.  Prior to being used for qPCR, all 
primer sets were tested with conventional PCR.  See Table 2 for primer information 
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Table 2.  Primer sequences used for this study. 
GAPDH      
 Tm (°C) GC content (%) Sequence (5’-3’) Amplicon length 
Forward 55.4 55.0 CACAGTCAAGGCTGAGAATGG  
Reverse 54.7 55.0 CGATGCCAAAGTTGTCATGG  
    300bp 
TRPV1     
 Tm (°C) GC content (%) Sequence Amplicon length 
*Forward 56.2 55.0 GTGATCGCTTACAGCAGCAG  
*Reverse 55.0 55.0 CGGTGACTCGGAAATAGTCC  
    238bp 
TRPV1.b     
 Tm (°C) GC content (%) Sequence Amplicon length 
*Forward 51.2 42.9 TACACAGACAGCTACTACAAG  
*Reverse 53.4 50.0 ATGACGGTTCCCGATCTT  
    471bp 
TRPV1.β      
 Tm (°C) GC content (%) Sequence Amplicon length 
Forward 51.7 50.0 GTTCTGGAGAACCGTCAT  
Reverse 51.6 45.0 CACAAACAAACTCTTGAGGG  
    312bp 
TRPV1.var     
 Tm (°C) GC content (%) Sequence Amplicon length 
Forward 55.7 55.0 ATCATCCAGGGACTAGCCTC  
Reverse 56.8 52.3 CAGCAGGAACTTCACAATGGC  
    121bp 
TRPV1.E7     
 Tm (°C) GC content (%) Sequence Amplicon length 
Forward 59.3 61.1 AACTCCACCCCACGCTGA  
Reverse 57.6 57.8 CGGTTCAAGGGTTCCACGA  
    307 
NPY     
 Tm (°C) GC content (%) Sequence Amplicon length 
Forward 49.6  47.4 GACAGAGATATGGCAAGAG  
Reverse 48.9 47.4 CTAGGAAAAGTCAGGAGAG  
    148bp 
Gap43     
 Tm (°C) GC content (%) Sequence Amplicon length 
Forward 51.0 50.0 CCTAAACAAGCCGATGTG  
Reverse 49.7 44.0 TTTGGCTTCATCTACAGC  
    150bp 
* = primer sequences acquired from Charrua et al. (2007). 
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 Two different qPCR machines were used during this study—a StepOnePlus 96-
well real-time machine from Applied Biosystems, and a Rotor-Gene Q from Qiagen.  For 
all 2-step reactions performed on the Rotor-Gene Q, Express SYBR GreenER master mix 
(Invitrogen) was used.  The following reaction conditions were used: 50°C UDG 
incubation (2’). 95°C Hot start (2’) [95°C (20”), 60°C (30”), 65°C (60”)]40.  For all 2-step 
reactions performed on the StepOnePlus, Power SYBR Green master mix (Applied 
Biosystems) was used.  The following reaction conditions was used: 95°C (10’) [95°C 
(15”), 60°C (60”)]45.  All 1-step reactions were performed on the StepOnePlus machine 
using the Power SYBR® Green RNA-to-CT™ 1-Step Kit  (Applied Biosystems).  
Reaction conditions for 1-Step reactions were as follows: 48°C Reverse Transcription 
(30’), 95°C AmpliTaq activation (10’), [95°C  (15”), 60°C (60”)]40.  Samples were 
prepared in 0.2mL PCR tubes or 48 well plates, and all final reaction volumes were 
20µL. 
 For all reactions performed on the Qiagen machine, the “Noise Slope Correct” 
analysis setting was applied in order to minimize background fluorescence.  No 
equivalent setting was available for the StepOnePlus machine.  However, a threshold 
value of 0.1 was selected for all reactions using the StepOnePlus machine.  A melt curve 
analysis was performed after each reaction to ensure that a single product was being 
amplified and to help minimize the occurrence of primer-dimer. 
 Visual analysis of amplified cDNA products were analyzed via an ethidium 
bromide stained agarose gel.  All gels were 2.5% and run in 1x TAE buffer for 100 
minutes at 100 volts. 
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Subcloning and sequencing 
 cDNA clones for TRPV1.b, TRPV1.can, TRPV1.β, and TRPV1.E7 were 
generated using the TOPO TA cloning kit (Invitrogen).  cDNA samples were generated 
by conventional PCR, using the primers listed above.  Single product formation was 
verified by gel electrophoresis.  Following PCR, the samples were purified using the 
Minelute PCR Purification Kit (Qiagen), either directly from PCR product or isolated 
from a gel.  The cDNA samples were ligated into the pCR®2.1-TOPO® Vector, which 
was then transformed into Mach1TM-T1R chemically competent cells. 
 Plasmids were harvested using the PurelinkTM Quick Plasmid Miniprep kit 
(Invitrogen).  They were screened for successful insertion with PCR, using M13 primers, 
and gel electrophoresis.  Plasmids carrying inserts were sequenced using the BigDye® 
Terminator Sequencing kit using both the forward and reverse M13 primers (Applied 
Biosystems).  They were then entered into the BLAST algorithm for confirmation.  
Confirmed sequences were then entered into the ClustalW alignment program alongside 
predicted DNA sequences, which were generated by me ahead of time.   Sequence data 
for TRPV1.E7 and TRPV1.can were kindly provided by Metis Hasipek and Karina Pena, 
respectively. 
Immunohistochemistry and confocal microscopy 
 DRGs from two rats, one control and one CCI, were used for fluorescent 
microscopy.  The CCI rat underwent the same surgery as described above.  However, 
prior to the surgery, the plantar region of the rat’s right rear paw was injected with DiD 
Dye (Molecular Probes), which is a retrograde tracer and will stain all DRG neuronal 
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cells that innervate the region.  The control rat was also injected with the retrograde dye 
also under anesthesia (50mg/kg).  Twelve days post-treatment, all DRGs from lumbar 
levels 2-6 were removed and immediately submerged in a 4% paraformaldehyde 1X 
phosphate buffer saline (PBS).  They were stored at 4°C until processed.   
 To cryoprotect the tissue samples, they were placed in a 30% sucrose 1X PBS 
solution for 4 hours.  Approximately 1/3 of the solution was then removed and replaced 
with Optimal Cutting Temperature (OCT) compound (Sakura) and incubated on a 
rocking shaker overnight.  The samples were then mounted in OCT and cut into 20µM 
slices on a cryostat.  Care was taken to orient the DRGs in the OCT so that samples were 
cut starting with the end distal to the spine to the proximal end.  Slices were thaw-
mounted onto critically-cleaned slides and post-fixed in a 4% paraformaldehyde 1X PBS 
solution.  The slides were then washed twice in 1X PBS and stored in 1X PBS until 
stained.  Prior to staining, the slices were permeabilized in a 0.3% Triton-X 100 1X PBS 
solution, and then washed twice more in 1X PBS.  The tissue samples were treated with 
20µL of the primary antibodies and incubated overnight at 4°C.  The following primary 
antibodies were used: 1:50 mouse anti-rat Neurofilament (Neuromics), 1:50 rabbit anti-
rat TRPV1 (Santa Cruz Biotechnology).  The sections were then washed three times in 
PBS and incubated overnight with secondary antibodies conjugated to Alexa-546 
(Molecular Probes), or FITC (Santa Cruz Biotechnology), and diluted 1:100 in PBS.  
Sections were washed in 1X PBS and mounted in Prolong-Gold (Invitrogen).  Fifteen 
Superlab III students participated in the staining and imaging of the tissue sections under 
the guidance of myself and Dr. John Pollock.    
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 Fluorescent images were collected by Dr. John Pollock using a Leica TCS SP 
spectral confocal microscope, which facilitates acquisition of multicolor images.  
Relative expression of TRPV1 was determined by comparing it to expression of DiD, 
whose expression is not affected by the CCI surgery.  This was done for neurons from 
control DRGs and CCI DRGs.  The relative expression of TRPV1 from each tissue 
sample and the difference between the two was recorded.  
Statistical analysis 
 The α level was 0.05 for all statistics.  All statistical tests were performed using 
SPSS software, version 18 for the Windows operating system (SPSS Inc., Chicago, IL).  
One-way ANOVA tests were performed to determine statistical significance of the 
quantitative real-time PCR studies.  Kruskal-Wallis One-way ANOVA by Ranks tests 
were performed to determine the statistical significance of the mechanical and thermal 
behavioral data.   Assistance with statistical analysis was kindly provided by Dr. Sarah 
Woodley and Dr. Dave Somers. 
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Chapter 3 
RESULTS 
 
Chronic constriction injury surgery causes pain 
 Visual observations of the rats’ behavior suggested that the CCI surgery had 
induced a chronic pain state in the affected animals.  During both tests, the rats would 
display nocifensorous behaviors, such as paw-licking, paw-waving, paw-guarding and 
defensive posturing.  The behaviors were also observed to be more severe at day 11 than 
at day 8.  The rats were also observed limping in their cages, favoring the affected paw, 
and minimizing the amount of weight it supported.  However, these visual observations 
were not substantiated by the results of the thermal and mechanical behavioral testing. 
Thermal hyperalgesia 
One of the most common symptoms of CCI-induced neuropathic pain in rats is thermal 
hyperalgesia, which is an elevated response to a non-painful or mildly painful heat 
source.  Thermal hyperalgesia was assessed by comparing the normalized mean 
withdrawal latencies (pain scores) from a radiant heat source of the CCI-treatment, sham-
treatment, and control groups.  At day 8 post-surgery, the mean withdrawal latency for 
the CCI-treatment, sham-treatment, and control groups were -0.31±1.87, 2.11±0.74, and 
2.11±0.86, respectively (Figure 7).  The CCI-treatment group was not significantly 
different from the sham-treatment or control group Nor was the sham-treatment group 
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different from the control group.  At day 11 post-surgery, the mean withdrawal latency 
for the CCI-treatment group, sham-treatment group, and control group were -1.16±0.65, 
0.41±1.54, and -0.74±2.67, respectively.  Though lower than either the control or sham-
treatment group, the CCI-treatment group was not significantly different from either.  The 
sham-treatment group was also not significantly different from the control group. These 
data cannot be used as evidence that the CCI procedure caused a greater amount of 
thermal hyperalgesia than the sham surgery, or that the procedure caused thermal 
hyperalgesia at all.  See Figure 7. 
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Figure 7. Thermal hyperalgesia in the right rear paw. 
Bars represent the mean ± standard deviation (SD) normalized withdrawal latency from a 
radiant heat source for each treatment group at day 8 and 11 post-surgery.  Lower 
threshold values indicate that the animals were experiencing an increased amount of 
thermal hyperalgesia.  No significant differences were found between any treatment 
groups at either time point.  The sample sizes for each treatment group at either time 
point are shown above the bars. 
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Mechanical allodynia 
 The other common symptom of CCI-induced neuropathic pain in rats is 
mechanical allodynia.  Allodynia occurs when a normally non-painful stimuli is able to 
evoke a pain response.  The 50% withdrawal method, as described previously, was used 
to calculate the normalized mean threshold for the three treatment groups at days 8 and 
11.  At day 8, the mean normalized 50% withdrawal threshold for the CCI-treatment 
sham-treatment, and control rats were, -0.73±1.54, 0.00±0.00, and 0.00, respectively 
(Figure 8). The CCI-treatment group was not significantly different from the sham-
treatment or control group At day 11, the mean normalized 50% withdrawal threshold for 
the CCI-treatment, sham-treatment, and control rats were -2.46±2.88, 0.00±0.00, 0.00, 
respectively.   The CCI-treatment group had a normalized mean withdrawal threshold 
lower than either the control rats or sham surgery rats, but was not statistically 
significant.  The fact that the CCI-treated animals did not have more negative scores at 
day 11 is due to only 2 of the 4 animals having lowered threshold values.  The other two 
animals showed no change in response to the mechanical stimuli. 
 At day 8, the mean normalized 50% withdrawal threshold for the sham-treatment 
group was not significantly different than the control group.  At day 11, the mean 
normalized 50% withdrawal threshold for the sham-treatment group was not significantly 
different from the control group.  Though the CCI-treatment group did have a lowered 
mean threshold value from the control group, it was not as great of a difference as has 
been recorded in previous studies by Zeyzus [66] or Somers [95].  For comparison, the 
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CCI-treatment rats from the study by Zeyzus had a normalized withdrawal mean of -
5.0±3.98 day 11 post-surgery. 
 Fewer nocifensive behaviors were observed during the mechanical testing.  The 
most common behaviors seen were weight shifting, to reduce the amount of support the 
affected paw had to contribute, and paw curling, which reduced contact between the 
plantar surface with the wire-bottom.  These behaviors were also not recorded. 
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Figure 8. Mechanical allodynia in the right rear paw. 
Bars represent the mean normalized 50% withdrawal threshold from calibrated Semmes-
Weinstein monofilaments (g) for only the chronic constriction injury treatment group.  
Error bars represent standard deviation.  No changes in withdrawal thresholds were 
recorded for the sham-treatment group or control group, and are not shown here.   Lower 
scores indicate that the animals’ threshold for mechanical stimuli have been lowered.  
There is no significant difference between the control group and the CCI-treatment group 
at either time point.  Sample size for the CCI-treatment group is shown above each bar. 
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Sequence data: TRPV1 and splice variants are expressed in DRG 
 Sequence data confirmed that the primers for TRPV1, TRPV1.b, TRPV1.β, were 
amplifying the correct gene or splice variant.  Gels for TRPV1 and the splice variants can 
be seen in Figure 9.  ClustalW results for TRPV1.can, TRPV1.b, and TRPV1.β can be 
seen in Figures 10-12. In the figures, the sequenced data are compared to published 
sequences in Genbank.  Since the variant specific primers were developed to span a 
spliced out region of the cDNA, the inclusion of the entire sequence corresponding to the 
location of primer site can be taken as confirmation of the existence of the variant.  The 
confirmation of these sequences guaranteed that all subsequent reactions were done in 
full confidence that the right product was being analyzed.  This is the first time that 
TRPV1.β has been isolated in rat DRG since it has only been previously documented in 
mice DRGs [71]. 
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Figure 9.  Gel visualization of TRPV1 and its splice variants following qPCR 
Lanes 1-3 show the relative intensity of TRPV1 (238bp).  Lanes 5-7 show the relative 
intensity of TRPV1.b (471bp).  Lanes 8-10 show the relative intensity of TRPV1.var 
(121bp).  Lanes 11-13 show the relative intensity of TRPV1.β (312bp).  The image was 
assembled from three separate gels. 
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SeqA Name      Len(nt)  SeqB Name      Len(nt)  Score 
===================================================== 
1    colony7   300      2    v1can     238      100   
===================================================== 
 
colony7         GTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTGTGATCGCTTACAGCAGCAGTGAGACC 60 
v1can           ---------------------------------GTGATCGCTTACAGCAGCAGTGAGACC 27 
                                                 *************************** 
 
colony7         CCTAACCGTCATGACATGCTTCTCGTGGAACCCTTGAACCGACTCCTACAGGACAAGTGG 120 
v1can           CCTAACCGTCATGACATGCTTCTCGTGGAACCCTTGAACCGACTCCTACAGGACAAGTGG 87 
                ************************************************************ 
 
colony7         GACAGATTTGTCAAGCGCATCTTCTACTTCAACTTCTTCGTCTACTGCTTGTATATGATC 180 
v1can           GACAGATTTGTCAAGCGCATCTTCTACTTCAACTTCTTCGTCTACTGCTTGTATATGATC 147 
                ************************************************************ 
 
colony7         ATCTTCACCGCGGCTGCCTACTATCGGCCTGTGGAAGGCTTGCCCCCCTATAAGCTGAAA 240 
v1can           ATCTTCACCGCGGCTGCCTACTATCGGCCTGTGGAAGGCTTGCCCCCCTATAAGCTGAAA 207 
                ************************************************************ 
 
colony7         AACACCGTTGGGGACTATTTCCGAGTCACCGAAGGGCGAATTCTGCAGATATCCATCACA 300 
v1can           AACACCGTTGGGGACTATTTCCGAGTCACCG----------------------------- 238 
                *******************************                              
 
 
 
 
Figure 10.  Sequence Data for TRPV1 
Sequence data was generated using the Big Dye Terminator kit from Applied 
Biosystems.  Cloned Sequences were compared to Genbank entries using the ClustalW 
program.  The 100% alignment score between the clone and the Genbank entry shows 
that the primers in these reactions successfully targeted TRPV1. 
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SeqA Name      Len(nt)  SeqB Name      Len(nt)  Score 
===================================================== 
1    colony4   522      2    TRPV1b    471      99    
===================================================== 
 
 
colony4         GAGGATGCTCGAGCGGCCCAGTGTGATGGATATCTGCAGAATTCGCCCTTTACACAGACA 60 
TRPV1b          --------------------------------------------------TACACAGACA 10 
                                                                  ********** 
 
colony4         GCTACTACAAGGCCCAGACAGCACTGCACATTGCCATTGAACGGCGGAACATGACGCTGG 120 
TRPV1b          GCTACTACAAGGGCCAGACAGCACTGCACATTGCCATTGAACGGCGGAACATGACGCTGG 70 
                ************ *********************************************** 
 
colony4         TGACCCTCTTAGTGGAGAATGGAGCAGATGTCCAGGCTGCGGCTAACGGGGACTTCTTCA 180 
TRPV1b          TGACCCTCTTGGTGGAGAATGGAGCAGATGTCCAGGCTGCGGCTAACGGGGACTTCTTCA 130 
                ********** ************************************************* 
 
colony4         AGAAAACCAAAGGGAGGCCTGGCTTCTACTTTGGTGAGCTGCCCCTGTCCCTGGCTGCGT 240 
TRPV1b          AGAAAACCAAAGGGAGGCCTGGCTTCTACTTTGGTGAGCTGCCCCTGTCCCTGGCTGCGT 190 
                ************************************************************ 
 
colony4         GCACCAACCAGCTGGCCATTGTGAAGTTCCTGCTGCAGAACTCCTGGCAGCCTGCAGACA 300 
TRPV1b          GCACCAACCAGCTGGCCATTGTGAAGTTCCTGCTGCAGAACTCCTGGCAGCCTGCAGACA 250 
                ************************************************************ 
 
colony4         TCAGCGCCCGGGACTCAGTGGGCAACACGGTGCTTCATGCCCTGGTGGAGGTGGCAGATA 360 
TRPV1b          TCAGCGCCCGGGACTCAGTGGGCAACACGGTGCTTCATGCCCTGGTGGAGGTGGCAGATA 310 
                ************************************************************ 
 
colony4         ACACAGTTGACAACACCAAGTTCGTGACAAGCATGTACAACGAGATCTTGATCCTGGGGG 420 
TRPV1b          ACACAGTTGACAACACCAAGTTCGTGACAAGCATGTACAACGAGATCTTGATCCTGGGGG 370 
                ************************************************************ 
 
colony4         CCAAACTCCACCCCACGCTGAAGCTGGAAGAGATCACCAACAGGAAGGGGCTCACGCCAC 480 
TRPV1b          CCAAACTCCACCCCACGCTGAAGCTGGAAGAGATCACCAACAGGAAGGGGCTCACGCCAC 430 
                ************************************************************ 
        EXON 6    EXON 8 
colony4         TGGCTCTGGCTGCTAGCAGTGGGAAGATCGGGAAC-GTCATAA 522 
TRPV1b          TGGCTCTGGCTGCTAGCAGTGGGAAGATCGGGAACCGTCAT-- 471 
                *********************************** *****   
 
 
 
Figure 11. Sequence Data for TRPV1.b 
Sequence data was generated using the Big Dye Terminator kit from Applied 
Biosystems.  No Genbank entry exists for TRPV1.b from rat DRG.  Therefore, cloned 
sequence (colony 4) was compared to the rat sequence missing the 180 nucleotides that 
constitute exon 7.  ClustalW was used for all comparisons.  Nucleotides highlighted in 
green represent the location of the forward primer.  Nucleotides highlighted in red and 
blue represent the location of the reverse primer.  Red nucleotides represent the 3’ end of 
exon 6 and the blue nucleotides represent the 5’ end of exon 8.  The score column in the 
table above the alignment represents the similarity between the two sequences. 
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SeqA Name         Len(nt)  SeqB Name         Len(nt)  Score 
=========================================================== 
1    TRPV1.beta   312      2    colony6      418      100   
1    TRPV1.beta   312      3    colony3      471      100   
2    colony6      418      3    colony3      471      99    
=========================================================== 
 
                EXON 7 
colony6         ATGATGCTCGAGCGGCC--CAGTGTGATGGATATCTGCAGAATTCGCCCTTGTTCTGGAG 58 
colony3         --GATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTGTTCTGGAG 58 
TRPV1.beta      ---------------------------------------------------GTTCTGGAG 9 
                                                                   ********* 
     EXON 8 
colony6         AACCGTCATGACATGCTTCTCGTGGAACCCTTGAACCGACTCCTACAGGACAAGTGGGAC 118 
colony3         AACCGTCATGACATGCTTCTCGTGGAACCCTTGAACCGACTCCTACAGGACAAGTGGGAC 118 
TRPV1.beta      AACCGTCATGACATGCTTCTCGTGGAACCCTTGAACCGACTCCTACAGGACAAGTGGGAC 69 
                ************************************************************ 
 
colony6         AGATTTGTCAAGCGCATCTTCTACTTCAACTTCTTCGTCTACTGCTTGTATATGATCATC 178 
colony3         AGATTTGTCAAGCGCATCTTCTACTTCAACTTCTTCGTCTACTGCTTGTATATGATCATC 178 
TRPV1.beta      AGATTTGTCAAGCGCATCTTCTACTTCAACTTCTTCGTCTACTGCTTGTATATGATCATC 129 
                ************************************************************ 
 
colony6         TTCACCGCGGCTGCCTACTATCGGCCTGTGGAAGGCTTGCCCCCCTATAAGCTGAAAAAC 238 
colony3         TTCACCGCGGCTGCCTACTATCGGCCTGTGGAAGGCTTGCCCCCCTATAAGCTGAAAAAC 238 
TRPV1.beta      TTCACCGCGGCTGCCTACTATCGGCCTGTGGAAGGCTTGCCCCCCTATAAGCTGAAAAAC 189 
                ************************************************************ 
 
colony6         ACCGTTGGGGACTATTTCCGAGTCACCGGAGAGATCTTGTCTGTGTCAGGAGGAGTCTAC 298 
colony3         ACCGTTGGGGACTATTTCCGAGTCACCGGAGAGATCTTGTCTGTGTCAGGAGGAGTCTAC 298 
TRPV1.beta      ACCGTTGGGGACTATTTCCGAGTCACCGGAGAGATCTTGTCTGTGTCAGGAGGAGTCTAC 249 
                ************************************************************ 
 
colony6         TTCTTCTTCCGAGGGATTCAATATTTCCTGCAGAGGCGACCATCCCTCAAGAGTTTGTTT 358 
colony3         TTCTTCTTCCGAGGGATTCAATATTTCCTGCAGAGGCGACCATCCCTCAAGAGTTTGTTT 358 
TRPV1.beta      TTCTTCTTCCGAGGGATTCAATATTTCCTGCAGAGGCGACCATCCCTCAAGAGTTTGTTT 309 
                ************************************************************ 
 
colony6         GTGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAA 418 
colony3         GTGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAA 418 
TRPV1.beta      GTG--------------------------------------------------------- 312 
                ***                                                          
 
colony6         ----------------------------------------------------- 
colony3         GCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTC 471 
TRPV1.beta      ----------------------------------------------------- 
 
 
 
Figure 12.  Sequence alignment of cloned TRPV1.β  sequences 
Sequence data was generated using the Big Dye Terminator kit from Applied 
Biosystems.  No Genbank entry exists for TRPV1.β from rat DRG.  Therefore, cloned 
equences  (colonies 3 and 6) were compared to rat sequences missing the final 30 
nucleotides from exon 7.  ClustalW was used for all comparisons.  Nucleotides 
highlighted in green represent the location of the reverse primer.  The nucleotides 
highlighted in red and blue represent the location of the forward primer, which straddles 
the truncated exon 7 and canonical exon 8.  The red nucleotides are the 3’ end of exon 7 
and the blue nucleotides are the 5’ end of exon 8.  In this alignment, two cloned 
sequences were compared to the recorded sequence for TRPV1.β. 
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Quantification of TRPV1 mRNA and its splice variants in normal and CCI 
DRG 
 
 Quantitative PCR (qPCR) and the comparative CT method [97] were used to 
determine if the CCI treatment altered the mRNA expression of TRPV1, TRPV1.b, 
TRPV1.β, and TRPV1.var. 
 In total, 22 DRG, divided among the three treatment groups, were analyzed via 
qPCR.  This number includes both the ipsilateral (right) and contralateral (left) level 5 
DRG from each animal.  For the sake of clarity, the term technical replicate must be 
defined before describing the comparative Ct method.  The term technical replicate refers 
to the number of individual qPCR reactions conducted for a single gene using a single 
tissue sample as the source.  In this case, 3 technical replicates and one no-template-
control reaction were performed for each gene from each tissue sample.  During the 
amplification stage of qPCR, the increase in amplicon concentration can be measured 
indirectly by the increase of fluorescence emitted by SYBR green.  SYBR green is a dye 
that intercalates in between nucleotides in DNA molecules, and the DNA-dye complex 
will fluoresce when exposed to a 488nM wavelength.  As the proportion of target cDNA 
is increased through PCR amplification, SYBR green has more targets to intercalate into 
and increase the fluorescence. 
 The comparative Ct method of quantification measures the change in mRNA 
expression of a gene of interest (GOI) relative to the mRNA expression of a control 
gene—a gene that is highly expressed and not subject to change in response to the 
treatment.  Therefore, while the GOI is subject to change in response to the treatment, the 
control gene is not.  In this experiment, Glyceraldehyde 3-phosphate dehydrogenase  
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(GAPDH) was used as the control gene.  GAPDH is an important enzyme in glycolysis.  
During the course of the experiment, the fluorescence emitted by each gene will cross an 
arbitrarily chosen threshold.  The cycle number at which the fluorescence breaks that 
barrier is referred to as the Ct value.  Since the control gene should have a much higher 
initial concentration than the GOI, the cycle number (Ct value) at which it crosses the 
threshold will be much lower than the GOI, presuming that each gene comes close to the 
theoretical doubling that occurs during each cycle of PCR.  Following each experiment, 
the 3 technical replicates for each GOI were averaged, as were the GAPDH technical 
replicates.  See Figure 13 for an example of raw qPCR data.  A ΔCt value for one gene 
from one tissue sample was calculated by subtracting the average Ct value for GAPDH 
from the average Ct value for the GOI.  This is represented more clearly with the 
following formula: 
 
    ΔCt = (mean GOI Ct ) – (mean GAPDH Ct), for one tissue sample. 
 
Once the ΔCt values were calculated from all biological replicates for a single GOI, they 
were imported into an Excel spreadsheet.  The next step in the comparative CT method is 
the calculation of ΔΔCt values.  This is done by subtracting the ΔCt of an experimental 
sample (either CCI or sham) from the ΔCt of a control animal, which is represented by 
the following calculation: 
 
    ΔΔCt= (ΔCt from Control animal) – (ΔCt from Experimental animal) 
 
The significance of this value is that it represents a shift in cycle number of the GOI 
relative to GAPDH between the control sample and the experimental sample.  If the value 
is positive, then the amount of starting DNA in the experimental sample is greater than in 
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the control sample, and if the value is negative, the opposite is true.  The final step that 
must be taken to determine the relative change in gene expression is to transform the 
ΔΔCt value into fold-change values, which is done as follows: 
 
    Fold Change = 2(ΔΔCt)  
 
This value represents the change in expression of one experimental tissue sample (CCI or 
Sham) relative to one control tissue sample.  In this experiment, 4 ipsilateral CCI, 4 
ipsilateral Sham, and 3 ipsilateral control samples were focused on.  To fully assess the 
effects of the procedure, a ΔΔCt value was generated for each CCI tissue by comparing it 
against each control tissue sample.  Each sham sample was also compared to each control 
sample in the same manner.  This combinatorial approach was done for each gene and 
gene isoform.  Once all of the different ΔΔCt values were generated, the mean and 
standard deviation were calculated.  These averaged values were then graphed to 
compare them to the control.  Fold Changes for controls were calculated similarly to the 
others by generating ΔΔCt values for each control tissue sample relative to the other 
control tissue samples.  A mean and standard deviation was calculated for this group as 
well. 
Zeyzus [66] demonstrated that there was no significant difference in TRPV1 expression 
between control, sham, and CCI animals at day 9; they were not analyzed in this study.  
Similarly, her study did not find any significant difference in TRPV1 expression in DRG 
levels 3 or 4 at day 12, so they were not included in this analysis. 
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Figure 13.  Quantitative PCR Data. 
(A) Quantitative PCR plot generated using cDNA from a control ipsilateral L5 DRG.  
The red arrowhead is pointing at the triplicate curves of GAPDH and the turqoise 
arrowhead is pointing at the triplicate curves of TRPV1.  The difference in cycle 
thresholds (ΔCt) is 5.12. 
(B) Quantitative PCR plot generated using cDNA from a CCI ipsilateral L5 DRG.  The 
red arrowhead is pointing at the triplicate curves of GAPDH and the turquoise arrowhead 
is pointing at the triplicate curves of TRPV1.  The ΔCt is 3.92.  The difference, or ΔΔCt, 
between 5.12 and 3.92 is 1.2.  This value means that the starting amount of TRPV1 
transcript in the CCI DRG is more than double that of the starting amount of transcript in 
the control DRG. 
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NPY and Gap43 
 For NPY, the data generated from trial 1 showed the greatest increase in 
expression in the CCI-treatment group.  The first trial generated mean fold change values 
for the CCI-treatment, sham-treatment, and control groups of 64.20±33.79, 6.49±6.21, 
and 1.44±1.34, respectively (Figure 14A). These data show that the CCI-treatment group 
was significantly different from both the sham-treatment group and the control group 
(p<0.001).  The sham-treatment group was not significantly different from the control 
group (p>0.05).  For the second trial, the mean fold-change value for the CCI-treatment, 
sham-treatment, and control group were 43.38±34.37, 2.92±2.02, and 1.2±0.78, 
respectively (Figure 14B). Here, the CCI-treatment group was significantly different from 
the control group (p<0.001) and the sham-treatment group (p<0.001), but the sham 
treatment group was not significantly different from the control group (p>0.05). 
 For Gap43, the data from the first trial showed the greatest increase in expression 
for the CCI-treatment group.  The mean fold-change values for the CCI-treatment, sham-
treatment, and control groups were 2.42±0.32, 1.52±0.51, and 1.00±0.07, respectively 
(Figure 14C).  These data show that the CCI-treatment group was significantly different 
from the sham-treatment and control groups (p<0.05).  The sham-treatment group was 
not significantly different from the control group (p>0.05).  For the second trial, the mean 
fold-change values for the CCI-treatment, sham-treatment, and control group were 
1.90±0.85, 0.93±0.14, and 1.01±0.20, respectively (Figure 14D).  Here, the CCI-
treatment group is not significantly different from the control group or from the sham-
treatment group (p>0.05).  The sham-treatment group is not significantly different from 
the control group.  Though not significantly different from the sham-treatment or control 
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group, the CCI-treatment group has a much greater mean fold-change value, and is close 
to being significantly different (p=0.072). 
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Figure 14.  Relative NPY and Gap43 Expression 12 days Post-Surgery using cDNA 
as Template Material 
(A)  Trial one analysis of NPY using polyA primed cDNA.  NPY expression from the CCI-
treatment group showed a 62.74-fold increase relative to the control group and a 57.7-fold 
increase in expression relative to the sham-treatment group.  These values are highly significant. 
(B) Trial two analysis of NPY using polyA cDNA.  NPY expression from the CCI-treatment 
group showed a 42.2-fold increase in expression relative to the control group, and a 40.5-fold 
increase in expression relative to the sham-treatment group.  These values are highly significant. 
(C) Trial one of Gap43 analysis using polyA primed cDNA.  Gap43 expression from the CCI-
treatment group showed a 1.4 fold increase in expression relative to the control and a 0.9 fold 
increase in expression relative to the sham-treatment group.  Both comparisons are significantly 
different. 
(D) Trial two of Gap43 analysis using polyA primed cDNA.  Gap43 expression from the CCI-
treatment group showed a 0.89-fold increase in expression relative to the control group and a 
0.98-fold increase in expression relative to the sham-treatment group.  Neither comparison was 
significantly different, although the trend supports the data from the first trial. 
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Expression of TRPV1 from DRGs removed 12 Days post-surgery  
 We first measured TRPV1 mRNA expression by using reverse-transcribed cDNA 
as the template material.  The results we got using this method were poor and unreliable, 
and we believe that using cDNA as the template material was an incorrect choice.  We 
then measured TRPV1 expression was measured by using mRNA as the starting material.  
The results using this method were much better and support our hypothesis that the CCI 
surgery increases TRPV1 expression.  The qPCR data generated using mRNA as the 
starting material also suggest that the rats experienced mirror pain. 
Analysis of cDNA generated by polyA priming 
 Two separate trials of analysis were conducted for each primer set using cDNA as 
the template material.  For each trial, an independently generated pool of cDNA was 
generated.  To prime the reverse-transcription process, primers that target the 
polyadenosine tail of mRNA were used.  These primers are not gene specific and will 
anneal to all mRNA.  For each trial, TRPV1 expression was measured once with both the 
Qiagen machine and the Applied Biosystems machine.  This resulted in four sets of data 
(Figure 15). Unless otherwise stated, all comparisons are between the ipsilateral mean 
fold change value of the CCI-treatment group to the ipsilateral mean fold change value of 
the sham-treatment and control groups. 
 The results from the first trial using polyA primed cDNA generated by the Qiagen 
machine (Figure 15C) were the only ones that were consistent with the results generated 
by Zeyzus [66].  Though not significantly different from the control animals, the CCI 
animals had a mean fold change value almost 200% greater than the control.  Likewise, 
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there is no significant difference in expression between the CCI animals and the sham 
animals, although the mean value for the CCI animals is greater.  The mean fold change 
value for the sham animals was somewhat elevated.  There was more variance in the 
control animals than expected.  The mean fold change values for the CCI-treatment, 
sham-treatment, and control groups are 2.96±3.23, 2.06±2.08, and 1.37±1.18, 
respectively. 
 The second trial using polyA primed cDNA and the Qiagen machine did not 
corroborate the trend observed in the first trial (compare Figure 15C with Figure 15D), 
nor the data generated by Zeyzus [66].  The mean fold value for the CCI-treatment, 
sham-treatment, and control groups were 0.65±0.24, 1.54±1.13, and 1.02±0.20, 
respectively (Figure 15D). No significant differences between the groups exist. 
 The second trial using polyA primed cDNA and the Applied Biosystems machine 
was similar to that of the second trial using the Qiagen machine (compare Figure 15A 
with Figure 15B).  No significant changes in expression were observed in either the CCI 
or sham groups.  The mean values for the CCI and Sham animals were actually slightly 
lower than the control group, which itself was slightly higher than expected.  The mean 
fold change values for the CCI-treatment group, sham-treatment group, and control group 
were 0.94±0.40, 0.94±0.47, and 1.14±0.62, respectively (Figure 15A).   
 
 The second trial using polyA primed cDNA and the Applied Biosystems machine 
was the least informative as it showed that all three treatment groups being elevated, and 
the sham-treatment group having the greatest mean fold value.  The mean fold value for 
the CCI- treatment group, sham-treatment group, and control group are 2.88±2.87, 
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4.70±5.90, and 1.96±2.43, respectively (Figure 15B).  Again, these data were not 
significantly different from each other. 
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Figure 15. Relative Gene Expression of TRPV1 using cDNA as Template Material 
(A) Trial 1 analysis using polyA primed cDNA and the Applied Biosystems Machine.  
TRPV1 expression in the CCI-treatment group is not significantly different from either 
the sham-treatment group or the control group.  Likewise, the mean fold change values 
are all very similar. 
(B) Trial 2 analysis using polyA primed cDNA and the Applied Biosystems machine. 
TRPV1 expression is not significantly different from either treatment group.  The mean 
fold change values for the sham-treatment and CCI-treatment are elevated though. 
(C) Trial 1 analysis using polyA primed cDNA and the Qiagen machine.  TRPV1 
expression in the CCI-treatment group is not significantly different from either the sham-
treatment group or the control group.  The mean fold change value for the CCI-treatment 
group is highest in this set of experiments. 
(D) Trial 2 analysis using polyA primed cDNA and the Qiagen machine. TRPV1 
expression in the CCI-treatment group is not significantly different from either the sham-
treatment group or the control group.  The mean fold change value is lower than the 
control, which would suggest expression has decreased. 
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TRPV1 expression using mRNA as the template material 
Because the qPCR data using polyA primed cDNA were inconclusive, qPCR experiments 
were performed using mRNA as the template material.  This form of qPCR analysis is 
different because the reverse-transcription and amplification steps are not separated.  It 
also utilizes gene specific primers instead of the nonspecific poly(dT) primers which 
target the polyA tail of all mRNA transcripts.  Using gene-specific primers results in only 
the reverse transcription and amplification of a single target.  The number of technical 
replicates performed for each tissue sample varied, depending on the remaining amount 
of RNA available.  As a consequence, it was impossible to run 3 technical replicates for 
TRPV1, TRPV1.b, and GAPDH for all tissue samples.  The data generated from the 1-
step experiment support the hypothesis that the CCI surgery increases the expression of 
TRPV1. The 1-step data also resemble the first trial data generated using the Qiagen 
machine.  The mean fold value for the CCI group was almost triple the Control, and the 
Sham mean value was twice as great as the control group.  The mean fold change value 
for the CCI-treatment group, sham-treatment group, and control group were 2.60±1.25, 
2.06±1.04, and 1.10±0.50, respectively.  Neither treatment group was significantly 
different from control group, or each other.  See Figure 16 for details. 
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Figure 16. Relative Expression of TRPV1 using RNA as Template Material 
Bars represent the mean fold change ± standard deviation (SD) of TRPV1 expression.  
The CCI procedure increased TRPV1 expression 2.6 fold relative to the control group.  
The sham surgery increased TRPV1 expression 2.06 fold relative to the control group.  
The CCI-treatment group was not significantly different from either the sham-treatment 
group or the control group (p=0.087).  The sham-treatment group was not significantly 
different from the control group.  The Applied Biosytems machine was used for this 
analysis. 
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Results from direct amplification of TRPV1 mRNA suggest mirror 
pain in CCI treated rats. 
 
 An interesting finding of this analysis is that a mean-fold comparison of the 
ipsilateral versus contralateral DRG samples for the CCI-treatment group shows them to 
not be significantly different (0.78±0.31). The mean ΔCt values for each group are also 
similar to one another (ΔCt Ipsilateral = 3.15, Contralateral = 2.70).  This suggests that 
both sides of the CCI-treatment animals experienced an increase in TRPV1 expression.  
Both sides also have mean ΔCts lower than either the sham-treatment or control groups.  
Mirror pain is a phenomenon where a unilateral injury causes bilateral pain [98]. 
Relative gene expression of TRPV1 splice variants 12 days post-surgery 
 Using primers that target individual splice variants, it was demonstrated that 
TRPV1.var, TRPV1.β, and TRPV1.b exist in rat DRGs.  Using cDNA as template 
material, it was found that the mean fold values for TRPV1.b were elevated in sham and 
CCI animals, but were not significantly different from the control animals.  Using mRNA 
as template material, TRPV1.b expression in the CCI-treatment, sham-treatment, and 
control group was unchanged and non-significant.  Expression of TRPV1.β was slightly 
elevated in sham and CCI animals using cDNA, but was not significantly different.  
TRPV1.var expression in CCI animals was relatively unchanged, if not lower than the 
control animals. 
TRPV1.b 
 TRPV1.b was the first variant examined in this study.  It is a splice variant of 
TRPV1 that is generated through the removal of the entire seventh exon.  Like TRPV1, 
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its expression was analyzed using both the Qiagen machine and the Applied Biosystems 
machine.  The four trials suggest as a group that both the chronic constriction injury 
procedure and the sham surgery increase the expression of TRPV1.b.  These trials also 
showed a great amount of variation within treatment groups, making any analysis less 
precise. 
 The first trial of TRPV1.b using polyA primed cDNA with the Qiagen machine 
shows a 100% increase in expression in the CCI-treatment group, and a 300% increase in 
expression in the Sham-treatment group.  The mean fold-change value for the CCI-
treatment group, sham-treatment group, and control group are 2.06±1.32, 3.55±1.24, and 
1.06±0.37, respectively (Figure 17C). The sham-treatment group is significantly different 
from the control group, but not from the CCI-treatment group.  The CCI-treatment group 
is not significantly different from either of the other groups. 
 The second trial using the Qiagen machine was different from the first trial.  Here, 
the mean fold-change value for the CCI-treatment group, sham-treatment, and control 
group are 7.66±8.09, 22.86±32.24, and 1.00±0.03, respectively (Figure 17D). The CCI-
treatment group was not significantly different from either the sham-treatment or control 
groups.  The sham-treatment group was not significantly different from the control group. 
 The reason for such large mean fold changes in the CCI-treatment and the sham-
treatment groups is that there was a large amount of variation in the ΔCt values.  For the 
sham-treatment group, the four ΔCts were 1.21, 3.47, 6.9, and 8.47.  The 1.21 ΔCt value 
is responsible for skewing the sham-treatment group.  If that low Ct value is excluded 
from the analysis, then the mean fold value for the sham-treatment group becomes 
5.80±7.50.  The 4 ΔCt values for the CCI-treatment group are 3.16, 6.62, 4.15, and 11.15.  
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If the 11.15 ΔCt is excluded, then the mean fold value for the CCI-treatment group 
becomes 10.18±7.81.  An additional problem that made this one set of experiments 
difficult is that no ΔCt value was generate for one control rat, meaning all fold change 
values were generated using only the two remaining control animals.  There was very 
little variation between the two control animals.  Their ΔCt values were 7.45 and 7.39. 
 The first trial using the Applied Biosystems machine found no significant 
difference between the mean fold change values of the three treatment groups.  The mean 
fold value for the sham-treatment group was especially high in this set of data too.  In this 
data set, the same sham-treatment animal that skewed the data in the previous data set 
also skews the data in this one.  The four ΔCts for the sham-treatment group are 6.53, 
9.38, 9.15, and 10.13.  The mean fold change for the CCI-treatment group, sham-
treatment (including all samples), and control group are 1.39±1.07, 4.40±6.44, and 
1.39±1.24, respectively (Figure 17A).  If the one sham animal is removed, then the mean 
fold value for the sham-treatment group becomes 1.63±1.15. 
 The second trial using the Applied Biosystems machine for TRPV.b showed that 
the the CCI-treatment group experienced an increase in expression, similar to that of the 
data generated by the first trial using the Applied Biosystems machine.  The mean fold 
change for the CCI-treatment group, sham-treatment group, and control treatment group 
are 11.46±10.71, 52.69±82.43, and 1.03±0.29, respectively (Figure 17B). The cause for 
the high mean fold value of the sham-treatment group is the same sham animal as from 
the second trial using the Qiagen machine.  When it is removed from the analysis the 
mean fold change for the sham-treatment group becomes 8.44±11.02. 
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 TRPV1.b was also analyzed using the 1-step qPCR technique, where RNA 
instead of cDNA is used as the template.  Like the 2-step data, the 1-step data found that 
there are no significant differences between the CCI-treatment, sham-treatment, and 
control groups.  The mean fold change values for the CCI-treatment, sham-treatment, and 
control groups are 1.33±0.55, 1.42±1.045, and 1.55±1.59, respectively (Figure 18). There 
were no wild ΔCt values in the sham-treatment group for this analysis.  This may suggest 
that the problem stemmed from the reverse-transcription process used to generate the 
cDNA for the 2-step analyses.   
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Figure 17.  Relative Gene Expression of TRPV1.b using cDNA 
(A) Trial one using polyA primed cDNA, TRPV1.b expression from the CCI-treatment group 
was not significantly different from either the sham-treatment group or the control group.  The 
mean fold value for the sham-treatment group was elevated relative to the other groups, but was 
not significantly different.  N = 3 for control group, N = 4 for the sham-treatment group, and N= 
4 for the CCI-treatment group. 
(B) Trial two using polyA primed cDNA, TRPV1.b expression from the CCI-treatment group 
was not significantly different from either the sham-treatment or control group.  The mean fold 
value for the sham-treatment group was much higher than either group, but was not significantly 
different.  The high value is due to a single sham-treatment sample having very high ΔΔCt values.  
N = 3 for control group, N = 4 for the sham-treatment group, and N= 4 for the CCI-treatment 
group. 
(C) Trial one using polyA primed cDNA, TRPV1.b expression from the CCI-treatment group was 
not significantly different from either the sham-treatment group or control group.  The sham-
treatment group was 2.5-fold greater than the control group and is significantly different.  The 
mean fold change for the CCI-treatment group is 2.8-fold greater than the control group, but not 
significant.  N = 3 for control group, N = 4 for the sham-treatment group, and N= 4 for the CCI-
treatment group. 
(D) Trial two using polyA primed cDNA, TRPV1.b expression from the CCI-treatment group is 
not significantly different from either the sham-treatment group or the control group.  The mean 
fold values for the sham-treatment group and CCI-treatment group were 21.6-fold and 6.6-fold 
greater than the control group, but were not significant.  N = 2 for control group, N = 4 for the 
sham-treatment group, and N= 4 for the CCI-treatment group. 
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Figure 18. Relative Gene Expression of TRPV1.b using mRNA 
Using mRNA as the template material, TRPV1.b expression from the CCI-treatment 
group was not significantly different from either the control group or the sham-treatment 
group.  The mean fold change for the sham-treatment and CCI-treatment were also not 
elevated relative to the control group. N = 3 for control group, N = 4 for the sham-
treatment group, and N= 4 for the CCI-treatment group. 
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TRPV1.β  
  
 TRPV1.β is an isoform of TRPV1 that is generated through the use of a cryptic 5’ 
splice site that truncates the seventh exon by 30 base pairs.  With primers that target 
TRPV1.β, I was unable to demonstrate in either trial that its expression was significantly 
altered by either the sham or CCI surgery.  Only the Applied Biosytem machine was used 
for this analysis.  For the first trial, the mean fold change values for the CCI-treatment, 
Sham-treatment, and Control groups were 0.91±0.54, 2.48±1.90, and 1.01±0.21, 
respectively (Figure 19A).  There was also no difference in expression between the 
ipsilateral and contralateral sides of the CCI-treatment and sham-treatment groups.  There 
was a slight increase in expression of the ipsilateral side relative to the contralateral side 
in the control group (1.92±0.50).   
 The second trial using polyA primed cDNA for TRPV1.β differed from the first 
trial.  The mean fold change values for the CCI-treatment, sham-treatment, and control 
groups were 3.06±3.46, 2.30±2.54, and 1.09±0.48, respectively (Figure 19B).  There 
were no significant differences for the ipsilateral versus contralateral comparisons for the 
CCI-treatment, sham-treatment, and control groups. 
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Figure 19. Relative Gene Expression of TRPV1.β  
(A) Trial one.  TRPV1.β expression from the CCI-treatment group was not significantly 
different from either the control group or the sham-treatment group.  The mean fold value 
for the sham-treatment group was elevated, surprisingly, but was not significantly 
different. N = 3 for control group, N = 4 for the sham-treatment group, and N= 4 for the 
CCI-treatment group. 
(B) Trial two.  TRPV1.β expression from the CCI-treatment group was not significantly 
different from either the control group or the sham-treatment group.  The CCI-treatment 
group did have an elevated mean fold value relative to the control group, but it was not 
significant. N = 3 for control group, N = 4 for the sham-treatment group, and N= 4 for the 
CCI-treatment group. 
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TRPV1.var 
 TRPV1.var is an isoform of TRPV1 generated through the retention of the intron 
between exons 5 and 6 and usage of an alternative start site.  Using primers that target 
TRPV1.var, I was unable to demonstrate that its expression was significantly altered by 
either the sham or CCI procedures, in either trial one or two.  For the first trial, the mean 
fold change for CCI, Sham, and Control were 1.19±1.13, 6.75±9.39, and 1.76±2.02, 
respectively (Figure 20A). For both the CCI-treatment and sham-treatment groups, a 
single rat had a Ct value 2 cycles lower than the other rats.  Removing that one rat from 
either group lowers the mean fold values of the CCI group, and the sham group to 
0.78±0.60 and 2.71±2.76, respectively. 
 For the second trial, the mean fold change for the CCI-treatment, sham-treatment, 
and control groups were 1.12±1.40, 1.28±1.18, and 1.20±0.77 (Figure 20B).  One rat in 
the CCI-treatment group did have a ΔCt 2.5 cycles lower than the others (9.94 vs. 12.48, 
13.05, and 13.08).  Eliminating that one value from the CCI-treatment group had a large 
effect on the mean fold change value for that group, changing it from 1.12±1.40 to 
0.42±0.19.  The other two groups did not have outliers like the CCI-treatment group. 
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Figure 20.  Relative mRNA Expression of TRPV1.var 
(A) Trial one using polyA primed cDNA, TRPV1.var expression from the CCI-treatment 
group was not significantly different from either the control group or the sham-treatment 
group.  Likewise, the mean fold change values for the sham-treatment and CCI-treatment 
groups were not very different from the control group. 
(B) Trial two using polyA primed cDNA, TRPV1.var expression from the CCI-treatment 
group was not significantly different from either the control group or the sham-treatment 
group.  Surprisingly, the mean fold change value for the sham-treatment group was 
elevated, though not significantly different. 
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Immunohistochemistry and confocal microscopy 
 The results from this experiment show that an increase in TRPV1 expression can 
be observed in level 5 DRGs, 12 days post-CCI.  To characterize the expression of 
TRPV1 in vivo, we analyzed sections of level 5 DRG from CCI treated and control rats 
with antibodies against TRPV1 and Neurofilament-M.  Additionally, the plantar region of 
the right rear paw of each rat was injected with DiD, a retrograde fluorescent dye.  DiD 
will only stain the neurons innervating that specific region of the foot.  In several 
sections, we observed robust fluorescence from medium (500-1000µm2) diameter 
neurons, stained with both NFM and TRPV1.  The average area of these 5 cells is 795 
µm2.  As expected, not all neurons were positive for the DiD tracer since only a discrete 
number of neurons reach the footpad.  However, in one tissue section, we observed 
robust fluorescence from neurons stained with NFM, TRPV1, and DiD (Figure 21A). 
Leica confocal software was used to analyze the expression of neurons positively stained 
for TRPV1 in the L5 DRG from the CCI treated rat and the Control rat.  The results show 
increased TRPV1 expression in neurons from CCI affected DRGs (Figure 21B). 
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Figure 21. Anti-TRP Immunohistochemistry and Comparison of Relative 
Fluorescence for Normal Versus CCI Cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. A. DiD retrogradely labeled 
DRG were processed for multi-stain 
confocal microscopy with anti-TRPV1 
and anti-Neurofilament antibodies.  The 
results reveal that some neurons co-
label with TRPV1 and DiD, while other 
neurons (*) lack both.  Scale bar is 
40µm2  B. Using Leica confocal 
software, we measured the relative 
fluorescence of TRP to DiD for 
representative CCI and control cells.  C. 
Summary of the relative fluorescence of 
TRPV1 shows that its expression is 
increased in CCI DRG.   
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Chapter 4 
DISCUSSION 
Summary 
 
 Transient Receptor Protein Vanilloid 1 (TRPV1) is an ion channel that responds 
to capsaicin, the molecule that imparts chili peppers with their fiery taste.  It is also a 
protein that integrates mechanical and thermal sensations, and is involved in nociception 
[35,60,99].  The surgical procedure used in this study is called chronic constriction injury 
(CCI).  It is a procedure designed to model the human neuropathic pain condition called 
Complex Regional Pain Syndrome II.  The CCI procedure was designed by Bennet and 
Xie in 1988 [92].  Previous reports on TRPV1 expression have demonstrated that nerve 
injuries increase its protein and mRNA expression.  The present study set out with two 
primary goals.  The first was to confirm that the TRPV1 expression is elevated in lumbar 
level 5 DRG ipsilateral to the CCI surgery of the sciatic nerve.  The second was to 
demonstrate that the CCI procedure alters the relative expression of three TRPV1 splice 
variants: TRPV1.var, TRPV1.b and TRPV1.β.  
 I have found that CCI did not cause an increase in thermal hyperalgesia and 
mechanical allodynia at day 12 post-surgery.  I did demonstrate that neuronal trauma took 
place only in the CCI group by analyzing the expression of two positive control genes, 
NPY and Gap43, consistent with previous studies [100,101].  I was unable to demonstrate 
that TRPV1 expression is significantly higher in the CCI treatment group, but the mean 
fold value is greater than either the control group or sham-treatment group.  The 
Karl A. Andersen 
 72 
expression of splice variant TRPV1.b is elevated in sham and CCI-treatment groups 
when cDNA is used for template material, but is not significantly different.  TRPV1.β 
and TRPV1.var expression is unaffected by the CCI surgery.   
Quantification of TRPV1 mRNA and its splice variants mRNA 
following CCI surgery 
TRPV1 
The results of this study show that there are no statistically significant differences in 
expression of TRPV1 between the CCI-treatment group and the sham-treatment group.  
That is, I am unable to demonstrate that the neuropathic pain model, CCI, was able to 
increase the expression of TRPV1 in total DRG in a way that was unique from the non-
neuropathic sham surgery, which did not include the ligation of the sciatic nerve.  This 
was true using both the Applied Biosystems real-time PCR machine and the Qiagen 
machine, and it was true for the studies using cDNA and mRNA.  That said, the 
experiments using mRNA did result in a mean increase in expression of TRPV1 by 
2.60±1.25 fold in the CCI-treatment group, which is 0.54 fold greater than the mean 
increase of expression of the sham-treatment group (2.06±1.04).  The studies using 
cDNA, however, were inconsistent and cannot statistically indicate that the CCI 
treatment was significantly different from the sham treatment.  These data are also 
consistent with the behavioral data, which showed that there were no increases in 
mechanical allodynia or thermal hyperalgesia in the CCI treated rats. 
 
 The mean fold increase reported here for the CCI-treatment group is consistent, 
and somewhat greater, than the mean fold increase reported by Zeyzus [66].  In her 
report, she found that mean TRPV1 expression from day 12, lumbar level 5 DRG 
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ipsilateral to CCI was 1.6-fold greater than control expression, which is 1.0 fold lower 
than the mean fold value for this study.  She also reported a mean 1.5 fold increase of 
TRPV1 expression in the ipsilateral DRG of CCI rats relative to the contralateral DRG of 
the same rats.  In the sham-treatment and control group, she found no difference in 
expression.  In this study, the data suggest that the CCI-treated rats had an increase in 
expression in both the ipsilateral and contralateral DRG.  The ipsilateral DRGs of the 
CCI animals relative to the contralateral DRGs had a mean fold change of 0.78±0.31, 
which is not statistically significant, but is the opposite of the results presented by Zeyzus 
[66].  It is an interesting finding and would suggest that the animal experienced allodynia 
and hyperalgesia in the unaffected paw, which is referred to as mirror pain.  No evidence 
from the behavioral data supports that position.  This finding is discussed in greater 
length below.   
 The lack of statistical significance was surprising since it has been previously 
shown that CCI and other pain models do induce an upregulation of TRPV1 protein and 
mRNA expression [62,63,102,103,104].  Other studies, however, have also found that 
neuropathic pain models do not cause an upregulation of TRPV1.  A study in 2007 
showed similar results to those found here.  That study, by Frederick et al. [105], found 
no significant increase in TRPV1 following CCI 7 and 14 days post-surgery.  Their 
hypothesis for why TRPV1 transcript levels were unchanged following CCI is that 
TRPV1 expression is controlled by unspecified post-transcriptionally regulated events.  
Another study by Michael and Priestley (1999) showed that TRPV1 expression in DRGs 
is actually decreased following sciatic nerve ligation [106].  Similar to the study by 
Michaels and Priestley, a study by Hudson et al. [62] found that TRPV1 expression 
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decreased in DRG neurons damaged by total or partial nerve ligation.  They did find that 
TRPV1 expression was increased in the remaining undamaged neurons.   
 Given the context of these other studies, it may be the case that the sutures tied 
around the sciatic nerves of the rats in this study were too tight, damaging a subset of 
neurons and diminishing the TRPV1 expression.  No post-mortem analyses of the sciatic 
nerves in this study were performed, so it is impossible to determine if the CCI surgery 
was done correctly, or if over-tightening or full ligation occurred.  My personal belief is 
that over-tightening probably did occur in at least one animal.  The previous studies 
analyzed mRNA expression or protein expression using antibodies or oligonucleotide 
probes against fixed DRG sections, allowing them to analyze individual neurons.  I 
analyzed TRP expression in homogenized tissue samples, so any increase in expression 
from uninjured neurons may have been diluted by the RNA from the injured neurons. 
 This study also used a small number of animals.  As a consequence, the over-
tightening of sutures in one animal may drastically affect the final expression data.  Only 
11 animals total were used, 4 in the CCI-treatment group, 4 in the sham-treatment group, 
and 3 in the control group. 
Quantification of splice variants of TRPV1 
 The second objective of this study was to determine the effects of the chronic 
constriction injury procedure on the expression of TRPV1 splice variants. To our 
knowledge, this is the first time that the effects of CCI on TRPV1.b, TRPV1.β, and 
TRPV1.var have been studied.  Each of these three splice variants are similar in that they 
each undergo alternative splicing within the N-terminal region of the gene.   
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I found that there were no statistically significant differences between the CCI- and 
sham-treatment groups with respect to TRPV1.β, TRPV1.b, and TRPV1.var.  The 
TRPV1.b data, however, appear to trend upward in the CCI-treatment group.  Three of 
the four analyses using cDNA found that TRPV1.b had increased mean fold change 
values, indicating an elevation in expression relative to control.  These are not supported 
by the study using mRNA though.  The mean fold value was greatest from trial 2 using 
both the Applied Biosystems machine and the Qiagen machine. 
 
 TRPV1.b is a splice variant of TRPV1 that was first identified in human brain 
tissue.  It is generated through the excision of exon 7 from pre-mRNA.  TRPV1.b is 
similar to the canonical transcript in every other respect.  To isolate TRPV1.b, I used 
primers that were published in a paper by Charrua et al. [83].  The forward primer is 
complementary to both the variant and the canonical transcript.  The reverse primer is the 
one that isolates TRPV1.b, as it is complementary to the last 9 nucleotides of exon 6 and 
the first 9 nucleotides of exon 8.  Of the 4 analyses that were conducted using cDNA as 
the template material, 3 showed TRPV1.b expression increasing in the CCI-treatment 
group.  These values ranged from a 2-fold increase to a 11-fold increase.  In all cases, 
these values were not statistically different from the control group or the sham-treatment 
group, as the standard deviations were very large.   
 The results for TRPV1.b, of the three, are perhaps the most interesting because 
they fail to corroborate the data generated by Charrua et al. [83].  In their study, they 
found that cyclophosphamide injection-evoked cystitis significantly downregulates 
TRPV1.b but does not alter the expression of TRPV1.  A number of possible reasons 
could contribute to the differences in findings.  The first reason is that they used a 
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different pain model in their attempt to alter the expression of TRPV1 and TRPV1.b.  
The second difference is that for their analysis they combined mRNA from lumbar level 
5 and 6, whereas I only used level 5 for my source of RNA.  Depending on the number of 
neurons from those two DRGs that innervate the bladder, they might be working with a 
larger population of neurons that experience changes in expression than I do.  The third 
reason is that they did their analyses 1 day and 3 days after they injected their irritant into 
the rats, whereas I did all of my analyses on tissue samples 12 days post-operation. 
Another possible explanation is the set of primers that was used to quantify TRPV1.b.  
Normally, primers designed for qPCR generate amplicons between 75 and 150 base pairs 
in length.  The primers designed by Charrua et al. that target TRPV1.b generate an 
amplicon of 471 base pairs, over three times the length suggested by Applied Biosystems.  
The length can impact the efficiency of the cycling, introducing unwanted variation into 
the ΔΔCt analysis.  And, unlike primers designed for canonical sequences, these primers 
can only target a specific set of nucleotides since the splice event is a deletion.  This 
results in a primer set that may be less efficient than desired, which is probably the case 
in this study.   
 It’s also possible that the discrepancies between the analyses using cDNA are a 
result of the reverse-transcription process.  The reverse transcriptase enzyme used in the 
process does not have as great of a processitivity as any other polymerase, so when 
reverse transcribing longer transcripts, it is more likely to fall off before generating a full 
length cDNA molecule.  The problem arises because the splicing events all occur in the 
5’-region, which is farthest away from the polyadenosine tail, and is where the primers 
bind to initiate reverse-transcription.  Even though each reverse-transcription reaction 
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started with the same amount of total RNA, it is possible that the distribution of TRPV1.b 
mRNA was not even, so the resultant product would not be uniform.  Though the data 
generated using mRNA shows no change in expression, which is different from the 
studies using cDNA, it still does not support the conclusion drawn by Charrua et al.  
Combined with the lowered processitivity, some of the variation between analyses can be 
explained.  
 During the course of the TRPV1.b experimentation, a problem was detected that 
affects all conclusions concerning it.  That problem is the fact that the seventh exon is 
spliced out in both TRPV1.b and TRPV1.5’sv.  This means that the primers used in this 
study cannot differentiate between the two isoforms, so no conclusion can be made about 
just one or the other.  The consequence of this ambiguity is that it is difficult, if not 
impossible, to say with certainty whether or not the TRPV1.b alone is being studied.  
This problem was not reported in the Charrua et al. paper. The significance of splicing in 
the N-terminal region is discussed in below. 
 TRPV1.β is a splice variant of TRPV1 that was first isolated in DRGs from 
C57BL/6 mice.  It is generated through the use of a cryptic 5’ splice site that truncates the 
end of exon 7 by 30 base pairs.  To analyze its expression, I generated primers that span 
the new exon-exon junction between the truncated exon 7 and the canonical exon 8.  The 
results of the 2 analyses using cDNA as the starting template are not consistent.  The 
mean fold value for the CCI-treatment group generated during trial 1 shows no change in 
expression relative to the control group, whereas the mean fold change generated during 
trial 2 shows a mean fold value 3.06.  Both analyses are not significant though, since the 
standard deviations of each are very large.  The mean fold values for the sham-treatment 
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group are actually similar to each other, differing by only 0.2 fold.  They are both also 
elevated above the control group, and neither of them is significantly different from the 
control groups.  All of the problems regarding primers and reverse-transcription that were 
discussed above also apply to TRPV1.β.  Despite those caveats, the conclusion that I 
must draw from these data is that TRPV1.β expression is not affected by CCI.  No other 
studies have been published that have analyzed its expression, so I have nothing to 
compare my results to.  
 TRPV1.var is an isoform of TRPV1 that was first identified in rat renal papilla 
cells by Tian et al. [78].  Its mRNA sequence is very similar to the canonical sequence 
except in two ways.  TRPV1.var is missing the first exon found in the canonical 
sequence, so it starts with exon 2 as its exon 1.  The greater difference between the 
canonical mRNA sequence and TRPV1.var is a retained intron found between exons 5 
and 6.  This 101 base pair intron introduces a frame shift error that truncates the protein 
to 253 amino acids.  The forward primer used to isolate this variant was positioned to sit 
inside of the retained intron, and the reverse primer was situated further downstream and 
complements both the canonical and variant transcript.   
 Analysis of the first trial show that the sham-treatment group experienced a large 
increase in expression since its mean fold change value was 6.75±9.39, but due to its very 
large standard deviation, it cannot be said to be significantly different from either the 
control or CCI-treatment group.  The CCI-treatment group showed virtually no change in 
expression relative to the control group, with a mean fold value of 1.2±1.1.  The control 
group showed a greater than expected amount of variation between its members, with a 
mean fold value of 1.76±2.02.  The mean fold value for the control group was generated 
Karl A. Andersen 
 79 
by comparing the control tissue samples to one another.  In contrast, the second trial 
showed no real changes in expression between the three groups, as the difference 
between the three was no greater than 0.2 fold.  Together, these data suggest that 
TRPV1.var expression is not affected by the CCI surgery.  If anything, they suggest that 
the sham surgery had a greater effect on its expression.  A reasonable explanation is that 
this variant is not expressed as highly in neurons than it is in renal tissue.  This would 
make detection harder and less consistent between samples.  A second related 
explanation could be that it is a variant that is not expressed uniformly between 
individuals.  The authors that described TRPV1.var originally state that they were able to 
isolate its transcripts in multiple animals and from multiple tissue types, but they do not 
explicitly discuss how abundantly it is expressed [78].  
 In contrast to the studies of TRPV1 and its splice variants, the studies of NPY and 
Gap43, the positive control genes, generated data that did fit the predictions.  There are a 
few explanations why the positive control studies worked and not TRPV1.  The first 
explanation is that the primers designed for NPY and Gap43 work better.  Unlike the 
primers for TRPV1, which all target parts of the mRNA toward the 5’-end, the primers 
for NPY and Gap43 target the 3’-end of the mRNA.  This is a more reliable location for 
primers since it is less affected by problems during the reverse-transcription process, as 
mentioned before.  The positive control primers are also more efficient since they can be 
positioned to target a region that will produce the least amount of unwanted primer-dimer 
products.   
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Pain assessment 
 A standard assessment of the efficacy of peripheral nerve injuries induced in 
murine animal models is to test for mechanical allodynia and thermal hyperalgesia of the 
plantar surface of the hind paws [92,95,107].  Unaffected animals generally do not react 
to the innocuous stimuli, and, if they do, it is generally to a relatively small degree.  In 
contrast, injured animals will generally withdraw their paws faster from a radiant heat 
source, or in response to the pressure of a calibrated monofilament.  Injured animals often 
will show physical changes that can be used as markers of the efficacy of pain models, 
including decreased weight, and altered gait. 
 This study shows that the CCI-treated rats, as a group, did display a slightly 
lowered threshold to pain, with respect to the mechanical pain assessment.  The mean 
normalized withdrawal score for all animals was calculated by comparing the number of 
foot withdrawals for the left and right paws at day 8 and day 11.  Neither time points, 
however, generated statistically significant results.  At day 8, of the 8 CCI animals tested, 
only 2 displayed a lowered pain threshold; at day 11, of the 4 animals tested, only 2 
displayed a lowered pain threshold.  Only one CCI-treatment animal responded at both 
days, and no sham-treatment or control animal responded at either time point.  Though 
only a trend, the data do support the time-dependent development of pain responses.   
 The thermal pain assessment data generated during this study cannot support the 
claim that the CCI-treatment animals had a significantly different mean withdrawal 
latency from either the sham-treatment or control group.  As a tool for determining the 
effectiveness of the CCI treatment, measuring the withdrawal latency in response to a 
radiant heat source is a lot less reliable.  It is a tool better served in the hands of an 
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experienced investigator since it can have more technical difficulties.  For example, 
keeping the animals to remain in place for the duration of the testing can be challenging.  
The test requires that the animal have all 4 paws on the surface of the glass before the 
heat is turned on, and they must remain in contact during the entire testing.  Rats, being 
rats, will investigate their surroundings and would often not remain stationary, 
interrupting the testing and forcing a restart.  As mentioned previously, the rats would 
also protect their affected paw by keeping it raised or lying on their side to keep the paw 
off the ground.  Occasionally, rats would stand on their rear paws to avoid the testing and 
to explore the Plexiglas chamber.  Unlike during the mechanical testing, where the 
animals were contained in a wire cage, the rats were kept in a Plexiglas container on top 
of a glass plate.  This resulted in their feces and urine affecting the testing by interfering 
with the sensor that would detect when a rat would lift its paw.  As a consequence, I 
would have to stop the testing, remove the animal from the box, clean the surface, return 
the animal, and allow it to rehabituate.  This increases the anxiety of already anxious 
animals, and may contribute to the large amount of variability of the mean normalized 
withdrawal scores. 
 Another technical difficulty of this study is the subjectivity of determining if a 
withdrawal is legitimate or not.  The definition of a foot withdrawal is the full, voluntary 
removal of the paw from the testing surface in response to the stimuli being tested.  The 
difficulty is determining, first, whether it is a legitimate withdrawal and not a shifting of 
weight or some other innocuous behavior, and second, whether or not the response is a 
result of the animal being in pain.  A too stringent measurement would underreport the 
pain that the animals are experiencing, and a too lax measurement would inflate the pain 
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the animals experience; in this experiment, I believe it is more likely that I underreported 
legitimate withdrawals than over-reported. 
 The lack of pained behavior from 7 CCI-treatment animals on day 8, and the lack 
of pained behavior from 2 CCI-treatment animals on day 11 suggests that the surgery was 
not uniformly performed.  Some animals may have had their sutures applied too tightly, 
resulting in a neuropathy instead of an inflamed sciatic nerve.  Previous studies that have 
compared the results of different pain models have found that there are unique treatment 
dependent results.  For example, a recent paper [108] found that crushing the sciatic 
nerve with forceps resulted in higher mechanical and thermal thresholds (meaning less 
pain was experienced), whereas an earlier paper showed that tightly ligating the sciatic 
nerve lowered mechanical and thermal thresholds slightly, but significantly [109].  
Despite being fairly similar models, the entire sciatic nerve is damaged in both, very 
different results were achieved.  Findings such as these reinforce how challenging it is to 
create reproducible pain models.  However, both studies were in agreement that CCI, 
when properly performed, causes the greatest decrease in mechanical and thermal 
thresholds.  Better surgeons will perform the CCI procedure consistently between 
animals, ensuring that each suture is properly tightened around the nerve.  To further 
reinforce the point that proper induction of a neuropathic pain state is challenging, a 
paper from 2004 found that even the type of bedding an animal recovers in does have a 
significant effect on the development of pain [110]. 
 A major limitation of this study is the population size of each group.  There were 
only 4 animals for the CCI and Sham groups, and there were only 3 animals for the 
control group.  Of the four CCI animals, only 2 showed signs of increased mechanical 
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allodynia, based on their difference scores.  Assuming that the same rate of surgical 
success were achieved, if not better, than the mechanical and thermal data would likely 
become statistically significant. 
Neuropeptide Y and Growth Associated Protein 43 
 The purpose of assaying Neuropeptide tyrosine (NPY) and Growth associated 
protein 43 (Gap43) expression was to provide additional molecular evidence that the 
sciatic nerve had been damaged following the CCI procedure.  The increase of expression 
of both of these genes following peripheral nerve damage has been documented in a 
number of studies [87,100,101].  The results from from both trials demonstrate that NPY 
expression did significantly increase in level 5 DRGs ipsilateral to the CCI-treatment 
animals, in comparison to the sham-treatment and control.  The increase in expression of 
Gap43 was statistically significant in the first trial but not the second trial.  The value of 
these data is that they demonstrate that there are statistically significant treatment-
dependent effects following CCI. 
 Within the pain transduction pathway, NPY is believed to have an anti-
nociceptive and anti-allodynic effect.  It is a neuropeptide that is released by DRG 
neurons into the central terminal, where it then binds to its receptors (Y1 and Y2) in the 
substantia gelatinosa [85].  The activation of Y1 and Y2 is believed to inhibit painful 
signals multiple ways.  One way is that Y2 activation causes the the release of glutamate 
from spinal synaptosomes to be attenuated.  A second way is that after peripheral nerve 
damage, Y2 activation reduces Ca++ channel conductance [85].  If NPY is upregulated 
following peripheral nerve damage, then Y1 and Y2 receptors will be activated more, 
further reduce channel conductance, and diminish pain signals to the brain.  This was 
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further demonstrated with Y1-/- mice [66,111].  These mice showed reduced latencies in the 
hot plate test, and showed greater allodynia following injection of complete Freund’s 
adjuvant into their hind paws.  Additionally, intrathecal injection of NPY did not 
diminish the nociception in these mice, whereas it normally does in wildtype mice [111].  
The increase in NPY in DRG neurons in this study, therefore, can be used as additional 
evidence that the animals likely experienced allodynia and hyperalgesia, even though the 
behavioral data does not bear it out. Gap43 is a protein found primarily in the 
cytoskeleton and plasma membrane.  It is a highly expressed growth-associated protein 
that plays a key role in axon guidance and connection formation during the development 
of the vertebrate nervous system [112,113].  In the mature nervous system, Gap43 
expression is much lower.  Following peripheral nerve damage, the expression of Gap43 
is upregulated and is associated with axonal regeneration [114,115].  Therefore, its 
differential expression can be used as measure of peripheral nerve damage.  The results in 
this study are consistent with the published literature and demonstrate that increased 
Gap43 expression is indicative of neuronal trauma occurring only in the CCI-treated 
animals.  Gap43 has not been shown to be involved in the pain transduction, so its 
upregulation cannot be associated with the onset of neuropathic pain, however.  
Likewise, neither of these genes can be used to demonstrate that the neuronal trauma 
experienced by these rats reflects the symptoms experienced during Complex Regional 
Pain Syndrome II. 
Mirror pain 
 One interesting piece of data that emerged from this study is the increased 
expression of TRPV1 in the contralateral (left) side of the CCI-treatment animals in the 
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1-step analysis.  A comparison of the ipsilateral versus contralateral fold changes 
revealed that there was no significant difference in expression between the sides.  
Additionally, the mean ΔCt values for the left and right sides were very close (Ipsilateral 
= 3.15, Contralateral = 2.70), and both were lower than either the control or sham-
treatment animals.   
 Mirror pain is a phenomenon that occurs in chronic pain conditions where pain is 
experienced on the side contralateral to the original injury [95].  Mirror pain is also 
responsible for allodynia in the contralateral side, so otherwise innocuous stimuli become 
uncomfortable and painful.  Presently, its origin has yet to be determined, although 
several mechanisms have been proposed.  These include the alteration of neurocircuits, 
which changes how sensory information is processed [98,116].  Milligan et al. [98] found 
in their study that the severity of mirror pain experienced by Sprague-Dawley rats is 
correlated with the level of immune activation caused by perisciatic microinjections of 
yeast cell walls.  Lower doses of the activator cause unilateral inflammation, and larger 
doses induce bilateral allodynia.  They also found that they could inhibit mirror pain with 
the intrathecal administration of proinflammatory antagonists, such as TNFbp.  They are 
unsure of how it is initiated, but they believe that the strong activation of 
proinflammatory molecules is able to activate glial cells in one side of the dorsal horn, 
and then propagate across to the other side via gap junctions and slow calcium waves. 
 Kleinschnitz et al. [117] reported similar data to that of Milligan et al. [98].  They 
found that CCI increased the mRNA expression of certain cytokines and chemokines in 
an NMDA receptor dependent manner.  Specifically, they were able to show that CCI 
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increases the mRNA expression of Interleukin-1β, Interleukin-10, and monocyte 
chemoattractant protein-1 in the contralateral DRG. 
 An earlier study by Oaklander and Belzberg [118] found that the unilateral nerve 
transection of the sciatic nerve distal to the DRG downregulates the sodium channel 
SCN10A bilaterally in rat DRGs.  The significance of this report is that spontaneous 
action potentials arising from the dorsal horn ipsilateral to the nerve injury may increase 
mechanosensitivity in the contralateral dorsal horn, causing mirror pain. Previous reports 
that they cite found that sciatic nerve transection increases the mRNA encoding for a 
different sodium channel subtype, SCN3A.  A change in the subtypes composing sodium 
channels in the dorsal horn, following nerve injury, may contribute to the generation of 
mirror pain. 
 Within the context of these other papers, the fact that TRPV1 mRNA expression 
increased in the contralateral (left) DRG seems less surprising.  The increase in 
expression would suggest that the animals may have experienced mirror pain, but without 
the corroborating behavioral data, the claim remains speculative.  Either way, the data 
presented here does support the claim that unilateral nerve injuries can affect the 
transcription of genes in the contralateral DRGs. 
Power analysis of real-time data 
 Because this study relied on a small sample size for each treatment group, it was 
thought that the power of this study might be below the commonly accepted power level 
of 80%.  To test this, a post-hoc power analysis was performed on the data generated 
from the TRPV1 real-time experiment using RNA as the template material.  The results 
of the power analysis found that the study, in fact, did not have enough animals in each 
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treatment group to achieve 80% power.  A minimum of 6 animals in each treatment 
group would be required to conclude with full confidence that a p-value of 0.087 is not 
statistically significant.  As a result, it cannot be definitively ruled that CCI does not alter 
the expression of TRPV1.  It still must be accepted, however, that the mean TRPV1 
expression of the CCI-treatment group is not significantly different from TRPV1 
expression in the sham-treatment or control groups. The results of this power-analysis 
also cannot be used to claim that the CCI procedure will generate statistically significant 
results if a minimum of 18 animals are used.  
Ankyrin repeats and the effects of alternative splicing within TRPV1 
 With the exception of TRPV1.var, which has a small 11 base pair deletion in the 
C-terminal region and TRPV1.son, which is a C-terminal fragment of TRPV1, the rest of 
the known splice events occur in the N-terminal cytosolic region.  Within the N-terminal 
region, the largest feature is the ankyrin repeat domain (ARD).  Initial analysis of the 
protein predicted there to be 3 ankyrin repeats [35] in the N-terminal region, but a 2007 
paper by Lishko et al. [39] demonstrated via crystallography that there are actually 6 
ankyrin repeats in TRPV1.  The discrepancy between the two papers may be explained 
by the fact that older methods of detecting the terminal ankyrin repeats in a domain had 
difficulty due evolutionary divergences between species [119].  The analysis by Lishko et 
al. determined that the ARD encompasses amino acids 101 through 364, and is encoded 
by exons 2 through 7.  Exon 7 only codes for the final 17 amino acids of the ARD, which 
means that the splice variant TRPV1.β does not affect the domain.  Other splice variants, 
such as TRPV1.5’sv, TRPV1.var, and TRPV1.b, do have splicing events that occurs 
within the ARD.  The variant TRPV1.5’sv has the greatest amount of splicing occurring 
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in the ARD since it starts with exon 5 and is missing the entire seventh exon.  See Figure 
22 for a cartoon comparing the different N-terminal regions of TRPV1 and its splice 
variants. 
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Figure 22.   Comparison of the Cytoplasmic N-Terminal Regions of TRPV1 and its 
Splice Variants 
 
(A)  Shown here is the canonical cytoplasmic N-terminal of TRPV1, which is coded for 
by exons 1-8 
(B)  Shown here is the spliced version of TRPV1.β.  10 amino acids are removed from 
the end of exon 7.  Red dotted lines indicate spliced out segment. 
(C)  Shown here is the spliced version of TRPV1.b.  The entire seventh exon is missing 
(D)  Shown here is the spliced version of TRPV1.var.  It utilizes an alternative 
transcriptional start site that skips exon 1 and it retains an intron between exons 5 and 6.  
Solid black line indicates retained intron. 
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 Ankyrin repeats are one of the most common amino acid motifs found in proteins.  
They were first characterized in yeast cell cycle regulatory proteins, and given the name 
ankyrin after the cytoskeletal protein, which has 24 of the repeats [120].  Ankyrin repeats 
are involved a variety of cellular functions, but are most commonly associated with 
protein-protein interaction.  In TRPV5 and TRPV6, the ARD has been shown to be 
necessary for functional channel assembly [121].  Lishko et al. showed that for TRPV1 
the role for the ARD is not involved in channel assembly, but actually channel 
modulation [39].  
 They showed that the ARD is involved with channel modulation based on how 
the binding of calmodulin and ATP have opposing effects on the channel.  During normal 
conditions, TRPV1 is in a sensitized state and will react to ligands or stimuli.  Following 
repeated stimulation, such as by repeated capsaicin applications, TRPV1 enters into a 
tachyphylactic state wherein it is resistant to further stimulation and will not open.  
During this desensitized state, it has been recognized that people experiencing pain find 
some relief.  The reason that they feel relief following the repeated capsaicin application 
is that calmodulin (CaM) binds to the ARD of TRPV1 and prevents the channel from 
opening.  The binding of CaM is Ca++ dependent and only occurs after TRPV1 opens up 
and allows for an influx of Ca++ ions.  As the Ca++ ions are re-sequestered, CaM is 
replaced by ATP, which returns the TRPV1 channel to a sensitized state.  The shared 
binding site for ATP and CaM is spread between the first three ankyrin repeats and 
involves 7 key residues.  Exons 2-4 code for these residues and are not affected by 
splicing events to form TRPV1.β, TRPV1.b, and TRPV1.var, but are affected by the 
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splicing necessary to form TRPV1.5’sv.  TRPV1.5’sv is missing the first 4 exons, and 
therefore lacks the ATP/CaM binding site. 
 Other known proteins that interact with the TRPV1 ARD include a variety of 
different kinases, including Protein Kinase A (PKA), Protein Tyrosine Kinase (PTK), and 
SRC Kinase [122,123].  These kinases mediate the effects of many of the intracellular 
molecules that sensitize TRPV1.  Therefore, the removal of phosphorylation sites could 
prevent the sensitization of TRPV1 to intracellular signaling molecules.  That might 
prevent or diminish the hyperalgesia or allodynia experienced by following TRPV1 
sensitization.  In terms of the splice variants studied in this project, only one residue in 
exon 7 is targeted by PKA: Tyrosine 370, and it is only removed in the formation of 
TRPV1.b.  The variant TRPV1.var has no transmembrane domain, so it would not be 
affected by the kinases.  The authors that described TRPV1.var suggest that it could be a 
decoy molecule for intermediate signaling molecules, allowing the canonical forms to go 
unaltered.  Though they do not explain how or where, the authors also suggest that 
TRPV1.var may interfere with proper channel architecture [78].  With regard to 
TRPV1.β, only 10 amino acids are missing from the end of exon 7.  Despite being a 
relatively small deletion, the loss of those 10 residues causes the protein to become quite 
unstable.  The deletion occurs in the region between the ARD and the transmembrane 
domain.  Only a small proportion of TRPV1.β proteins manage to make it into the plasma 
membrane.  Once inserted into channels, TRPV1.β causes the channel to become 
insensitive to capsaicin or protons.  This is an odd finding since the capsaicin binding site 
is located in the transmembrane domains, and the proton binding sites are extracellular.  
The authors conclude that TRPV1.β has a dominant-negative effect, and that its 
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upregulation may be a way to desensitize capsaicin sensitive cells without causing 
cellular death [71].   
 In contrast to TRPV1.β, and its 10 amino acid deletion, TRPV1.b is missing the 
entire exon 7 and is able to form functional ion channels that are temperature sensitive 
but not capsaicin or proton sensitive [70].  The authors make the argument that during 
times of inflammation, channels that have TRPV1.b as a subunit, or are made entirely of 
TRPV1.b, would only act as thermal transducers, potentially diminishing painful signals.  
Their hypothesis, however, seems to be contradicted by Charrua et al. [83] who found 
that TRPV1.b expression is downregulated in a cystitis rat model.  Charrua et al. seem to 
suggest that during non-painful conditions TRPV1.b keeps the TPRV1 channel from 
being too sensitive to capsaicin or protons, and during painful conditions TRPV1.b 
causes the TRPV1 channel to become more sensitive through its downregulation.  While 
not statistically significant, the trend of increased expression would support Lu et al., and 
their hypothesis that TRPV1.b helps to desensitize TRPV1 channels. 
 The original paper by Lu et al. [70] describing TRPV1.b, suggests that only a 
small population of cells within the DRG express the variant.  These nociceptors may be 
responsible for only responding to temperatures even higher than the canonical TRPV1 
protein.  How the removal of exon 7 effects this change is not clear from the paper, but it 
does say that this isoform is no longer responsive to protons or to capsaicin.  The 
suggestion is that the lack of exon 7 is affecting how capsaicin binds to its receptor site, 
which is located between transmembrane 2 and 3. 
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Immunohistochemical and confocal microscopy data 
 The result of the immunohistochemical data are that TRPV1 expression is 
increased in a subset of DRG neurons that innervate the plantar surface of the right rear 
paw of rats following CCI surgery.  We were able to demonstrate this through the use of 
a fluorescent retrograde neuronal tracer and fluorescent antibodies specific for TRPV1 
and Neurofilament-M, a protein expressed only in neuronal cells.  We showed that 
relative fluorescent intensity of TRPV1 expression relative to DiD expression was greater 
in CCI affected DRGs compared to DRGs from control animals.   
 As previously mentioned, TRPV1 is expressed primarily in neurons with 
medium-to-small, myelinated Aδ fibers and small neurons with unmyelinated C-fibers.  
What can be seen in Figure 23 is that TRPV1 is primarily being expressed in medium 
(500-1000µm2) sized neurons.  Neurons of this size are typically associated with Aδ delta 
fibers.  This is consistent with what is reported in the literature [124, 125].   In some 
studies, the expression of TRPV1 and other TRP proteins has increased in large neurons, 
but that was not documented here.  A study by Staaf et al. (2009) demonstrated that 
TRPML3, for example, was upregulated in larger diameter DRG neurons following the 
spared nerve injury [87].  Large neurons are normally associated with innocuous 
sensation, not nociception, but it is believed that they can be recruited into expressing 
TRPV1 during chronic pain states [87]. 
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Chapter 5  
FUTURE WORK 
Replication using larger sample sizes 
The lack of power in this study prevented us from demonstrating that there are significant 
differences in TRPV1 expression between the three different groups.  We lacked the 
necessary power because our sample size was to small to compensate for some of the 
surgical deficits we encountered.  We would like to replicate this study using the 
necessary animals to achieve statistical significance.  The preliminary data we generated 
from the immunohistochemical data was also intriguing, and we want to pursue that as 
well.  It would be interesting to see if we could generate isoform specific antibodies for 
this work.  We would also like to replicate the study primarily using direct from mRNA 
amplification.   
Analysis of other TRP genes and their splice variants 
 Splice variants have been isolated in many other TRP genes, including TRPV4, 
TRPM8, and TRPC1, among others [126].  TRPV4 and TRPM8 are both ThermoTRPs, 
just like TRPV1, so characterizing the contribution of their splice variants to the 
generation and maintenance of neuropathic pain conditions would further increase our 
ability to treat pain.  A TRP that has no known current splice variants is TRPA1.  It and 
TRPM8 are believed to be the primary detectors of cold, menthol, and mustard oil [27].  
Both it and TRPM8 are known to be upregulated in response to the CCI procedure.  We 
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would like to perform studies to determine if TRPA1 has splice variants, and what their 
contribution to neuropathic pain would be. 
Cell culturing of primary neurons or cell lines 
 As described above, one of the greatest difficulties of this kind of research is 
attaining adequate sample sizes to generate robust, significant data.  A reasonable 
alternative might be culturing primary neurons obtained from DRGs, or using 
immortalized rat neuronal cell lines instead of live animals.  The advantages of utilizing 
cell lines include infinite sample sizes, greater schedule flexibility, and unlimited 
amounts of RNA.  Additionally, using these cell cultures would be more humane, and in 
line with the idea of using fewer animals to generate comparable data.  The greatest 
disadvantage to this approach is that no behavioral data can be generated.  The other real 
challenge would be determining if the cells can be properly stimulated by pro-
inflammatory molecules to induce a differential expression of TRPV1.  The CCI method 
is intended to barely impinge the sciatic nerve, and create an inflammation around the 
sutures, so if the cells could be directly stimulated with pro-inflammatory molecules, 
there would be less reason to perform the surgeries and use rats.   
 Some work in this area has already been done.  One of the first studies to 
demonstrate the Nerve Growth Factor (NGF) directly affects TRPV1 expression was 
done using cultured DRG neurons.  Winston et al. (2001) [127] showed that TRPV1 
expression in cultures of adult rat DRG neurons increase in a NGF dose-dependent 
manner.  They measured the increase of TRPV1 in two ways.  The first way they 
measured NGF’s effect on TRPV1 expression was by measuring the release of calcitonin 
gene related peptide (CGRP) from DRG neurons.  Previous reports had shown that 
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capsaicin causes the depolarization of neurons and the release of CGRP.  The application 
of NGF in a dose-dependent manner resulted in the increase of TRPV1 channels that 
could be activated by capsaicin, allowing for a greater release of CGRP.  The second way 
they showed that NGF increases the expression was by using Northern blots to directly 
measuring the TRPV1 mRNA levels following NGF application.  Other similarly 
designed studies have been conducted to show that TRPV1 expression can be regulated 
by other intracellular pathways.  For example, a recent paper showed that administration 
of alpha 2-adrenoreceptor agonists can attenuate capsaicin-evoked substance P (an 
inflammatory molecule) release in cultured DRG neurons [128].   
 Cultures of DRG neurons can also be used to study TRPV1 splice variants.  The 
same paper that showed that TRPV1.b overexpression attenuates the sensitivity of 
TRPV1 to capsaicin, also showed that TRPV1.b can be isolated and analyzed in DRG 
cultures.  The role that splice variants play when inflammation or peripheral nerve 
damage has occurred is only beginning to be studied.  Using DRG cultures would allow 
scientists to more easily tease out what effects individual inflammatory molecules have 
on splice variant expression in vivo.  We know that NGF increases TRPV1 expression, 
but it is currently unknown if it has the same effect on its splice variants. 
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